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1. INTRODUCTION
Cholecystokinin (CCK) belongs to the family of brain-gut peptides. It was 
originally discovered in the gut and shown to influence pancreatic secretion and 
contraction of gall bladder. CCK is present in different biologically active 
molecular forms cleaved from a 115-amino-acid precursor molecule (pre-pro- 
CCK), including CCK-58, CCK-39, CCK-33, CCK-22, sulphated CCK-8 and 
CCK-7, unsulphated CCK-8 and CCK-7, CCK-5 and CCK-4 (Rehfeld and 
Nielsen, 1995). The С-terminal pentapeptide conserves the structural homology 
of these CCK sequences and also homology with peptide gastrin (Mutt, 1980). 
Full biological activity requires the octapeptide to be sulphated at the tyrosine 
in the seventh position from the C-terminus (Jensen et a l, 1982). Also, 
a-amidation of the C-terminus is essential for biological activity. The shortest 
biologically active form is С-terminal tetrapeptide, although it has much lower 
potency (Knight et a l, 1984).
CCK interacts with two receptor subtypes named according to their main 
distribution: CCKA (peripheral type) receptors, mainly located in the gastro­
intestinal tract, and CCKB (brain type) receptors that are abundantly found in 
the central nervous system (CNS) (Moran et al., 1986). These receptor subtypes 
can be described by pharmacological means on the basis of their affinity for the 
fragments of CCK. CCKA receptors are highly selective for sulphated ana­
logues of CCK (Wank et al., 1988; Wank et a l, 1990). CCKB receptors have 
high affinity not only for sulphated fragments but also for gastrin and nonsul- 
phated analogues of CCK (Saito et al., 1981; Saito et al., 1997). Therefore, 
CCKB receptors are also called CCKB/gastrin receptors (Wank, 1995). For 
CCKA receptors the minimal sequence for high affinity binding is CCK-8. 
CCK-4 is the shortest form required for binding to the CCKB receptors (Saito et 
a l, 1981; Durieux et a l, 1988).
The biggest problem in the studies on neuropeptides is their unstability and 
fast degradation by the peptidases. Selective, non-peptide antagonists with 
different chemical structures have been developed for overcoming this problem 
(Woodruff and Hughes, 1991). For CCKA receptors the compound of particular 
interest is devazepide (L-364,718 or MK-329) (Chang et al., 1986; Chang and 
Lotti, 1986). Devazepide interacts with CCKA receptors at low nanomolar 
concentration and it has also high selectivity for CCKA receptors. The selective 
antagonist for CCKB receptors is L-365,260 (Lotti and Chang, 1989). Both 
compounds are benzodiazepine derivatives with relatively long lasting efficacy 
in vitro and in vivo, and with oral bioavailability (Chang and Lotti, 1986; 
Woodruff and Hughes, 1991).
CCKB receptors in CNS are responsible for the modulation of various 
physiological processes including pain processing, learning and memory,
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motivation and anxiety (Singh et al., 1991; Costall et al., 1991; Shlik et al., 
1997). The first observation that administration of CCK-4 to healthy subjects 
can produce anxiety, dyspnea, and depersonalisation was made in the end of 
sixties (Rehfeld, 1992). In 1979 two papers described the first hints about 
anxiogenic-like behavioural action of CCK (Della-Fera and Baile, 1979; 
Ishibashi et al., 1979). Della-Fera and Baile studied the satiating effect of 
CCK-peptides and they found that intracerebroventricular injection of pen- 
tagastrin (CCK-5) induced foot stamping and vocalisations in sheep (Della-Fera 
and Baile, 1979). In 1984 Bradwejn and de Montigny demonstrated in the 
electrophysiological experiment that the anxiolytic drugs block the excitatory 
effect of CCK (Bradwejn and de Montigny, 1984). After that several human 
studies have revealed the implication of CCK-system in the neurobiology of 
anxiety and panic attacks (Bradwejn et al., 1991; Abelson and Nesse, 1994). 
Also the results obtained from the animal experiments have shown that the 
manipulations with CCK receptors can influence anxiety in the different behav­
ioural paradigms. CCK agonists inhibit exploratory behaviour of mice and rats 
in the elevated plus-maze (Harro et al., 1990; Harro and Vasar, 1991) and 
decrease the time spent in the aversive light compartment of the light/dark 
compartment test (Singh et al., 1991; Chopin and Briley, 1993). Moreover, 
CCKB antagonists have been shown to possess the anxiolytic-like properties in 
the ethological models of anxiety (Hughes et al., 1990).
The aim of the present study was the further clarification of the background 
of CCK-induced anxiety in rats. At first, the influence of pre-experimental 
stress on the exploratory behaviour of rats and the anxiogenic-like action of 
CCK agonist was studied. Moreover, we explored also the seasonal variations 
in the exploratory behaviour of rats and the role of CCK in those behavioural 
changes. In the second part of the experiment the individual differences in the 
exploratory behaviour in the elevated plus-maze and the role of CCK-ergic 
neurotransmission in these differences were studied. The third aim of the study 
was to investigate the interaction of CCK and endopioid mechanisms in the 
generation of anxiety in rats. Finally, as serotonin (5-hydroxytryptamine, 5-HT) 
has been shown to be an important mediator influencing the behaviour under 
aversive circumstances, the 5-HT and CCK interaction in the regulation of 
exploratory behaviour was studied.
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2. REVIEW OF LITERATURE
2.1. CCK in the Central Nervous System (CNS)
CCK was first described in the mammalian CNS as gastrin-like immuno- 
reactivity in 1975 (Vanderhaeghen et al., 1975). It is now generally believed 
that CCK is the most abundant neuropeptide in CNS (Rehfeld and Nielsen, 
1995). Of the multiple available fragments, the sulphated octapeptide of CCK is 
the predominant derivative (Dockray and Taylor, 1976). Radioimmunological 
studies have shown the localisation of CCK-like immunoreactivity (CCK-LI) in 
high amounts throughout the human brain with the highest levels (300- 
1200 pmol CCK-LI/g wet weight) in the neocortex (in the frontal and occipital 
regions) (Lindefors et al., 1993), hippocampus, and subiculum (Lindefors et al., 
1991). The intermediate amounts (100-500 pmol CCK-LI/g wet weight) have 
been found in several subcortical structures, including the caudate nucleus, 
putamen, nucleus accumbens, septum, ventromedial thalamus, periaqueductal 
grey, and substantia nigra (Emson et al., 1982; Taquet et al., 1988). Low 
amounts (<100 pmol CCK-LI/g wet weight) have been established in the globus 
pallidus, lateral thalamic nuclei, mesencephalic, and metencephalic nuclei 
(Lindefors et al., 1993). Structures containing few or no CCK neurones are the 
cerebellum, corpus callosum, internal capsule, anterior and posterior commis­
sures (Rehfeld et al., 1992; Rehfeld and Nielsen, 1995). In the cortex, CCK is 
present mainly in thin nerve terminals throughout all the cortical layers, slightly 
less in the molecular than in deeper layers (Rehfeld, 1978). Therefore the 
staining of CCK nerves produces general light staining of the entire cortex 
(Larsson and Rehfeld, 1979). Most of CCK positive neurones belong to the 
nonpyramidal types such as multipolar or bipolar, but some small pyramidal 
cells are also present (Sakamoto et al., 1984). Considerable evidence sug­
gests that CCK functions as a neurotransmitter (Crawley and Corwin, 1994; 
Vanderhaeghen and Crawley, 1985) and iontophoretic application of the 
peptide to the nervous cells produces the excitatory effect (Boden and Hill, 
1988; Liu et al., 1994). CCK is localised in the neurones, concentrated in the 
nerve terminals, and synthesised de novo in the nerve cells. The neuronal CCK 
is released by depolarisation, its inactivation occurs by enzymatic degradation 
and reuptake from the synaptic cleft. The effect of CCK could be interfered by 
means of suitable receptor antagonists (Rehfeld and Nielsen, 1995).
CCK is co-localised with several other neurotransmitters. Co-localisation 
with dopamine (Hökfelt et al., 1980), substance P (Skirboll et al., 1982), 
enkephalin (Gall et al., 1987), GABA (Hendry et al., 1984), and the corticotro­
pin-releasing factor (Mezey et al., 1985) is established. This widespread co­
localisation with the other neurotransmitters can be an anatomical support for
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the regulatory role of CCK in various brain functions. The application of 
modem techniques has identified two receptor subtypes to CCK: CCKA 
(peripheral) and CCKB (central) receptors. CCKA receptors are found mostly in 
the gastrointestinal tract and CCKB receptors are located mainly in the brain 
(Moran et al., 1986). Nevertheless, there are some exceptions to that rule since 
CCKA receptors are also found in the discrete regions of brain (area postrema, 
nucleus tractus solitarius, interpeduncular nucleus, and posterior hypothalamus) 
(Hill et a l, 1992). At the same time, CCKB receptors are established in the 
peripheral organs (de Weerth et a l, 1998). The highest densities of CCKB 
receptors in the brain are in the cerebral cortex, limbic system (the olfactory 
tubercles, hippocampus, nucleus accumbens, and amygdala), striatum, hypo­
thalamus, ventral tegmentum, and dorsal raphe nuclei (Innis and Snyder, 1980; 
Honda et a l, 1993). The weak to moderate signals of radioactive ligands have 
been detected in the cerebellum and spinal cord (Saito et a l, 1980; Gaudreau et 
a l, 1983; Moran et a l, 1986).
Table 1. Characteristics of cholecystokinin receptors (Shlik et al., 1997)
Nomenclature CCKA receptor CCKb receptor
Alternative Peripheral subtype Central subtype
names ССКв/gastrin receptor
Potency order 
of CCK ago­
nists
Caerulein>CCK-8s»gastrin=CCK-4 Caerulein>CCK-8s>gastrin=CCK-4
Agonists Caerulein Caerulein
CCK-8s CCK-8s
A71623 CCK-8us
A70874 CCK-4
JMV-180 Pentagastrin
BC264
Antagonists Proglumide Proglumide
Devazepide L-365,260
Lorglumide L-740,093
Lintitript (SR27897) LY288513
CI-988
Effector G-protein q/11 G-protein q/11
Gene CCKA CCKB
Structural 428-amino-acid sequence human P32238 447-amino-acid sequence human P32239
information 7TM 7TM
444-amino-acid sequence rat P30551 7TM 452-amino-acid sequence rat P30553 
7TM
Location in Human chromosome 4 Human chromosome 11
chromosomes Mouse chromosome 5 Mouse chromosome 7
Distribution Gall bladder, pancreas, pylorus, spinal Throughout the brain, stomach, vagus
cord, vagus nerve, limited brain areas nerve, kidneys
Functions Mediates actions of CCK on gall bladder Mediates actions of CCK on increases in
contraction, secretion of pancreatic en­ neuronal firing rates, nociception, anxi­
zymes, gastric emptying, inhibits feeding ety, respiration, inhibits dopamine-medi­
and respiration, potentiates dopamine- 
mediated behaviours and dopamine release 
in shell of nucleus accumbens
ated behaviours and dopamine release
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Despite the pharmacological evidence for the existence of the third and even 
the fourth receptor subtype, modem technology of cloning has supported the 
existence and distribution of only these two receptor subtypes (Wank et a l, 
1992; Wank et a l, 1992; Pisegna et a l, 1992; Lee et a l, 1993). In situ 
hybridisation technique has revealed a regional distribution of CCK receptor 
mRNA that generally parallels the distribution of radioligand binding sites (Hill 
and Woodruff, 1990; Honda et a l, 1993; Wank et a l, 1994). Only in the 
cerebellum, despite the positive hybridisation signal, the autoradiographic 
labelling of CCK receptors is not observed (Jagerschmidt et al., 1994).
2.2. CCK and anxiety
The ability of CCK to induce anxiety was first described by Jens Rehfeld 
during his military service in 1969. He injected tetragastrin (CCK-4) to the 
volunteers in order to investigate insulin secretion. He noticed that immediately 
after the injection of 70 |j,g of CCK-4 the soldiers became quiet and looked 
fearful (Rehfeld, 1992). In 1978, Rehfeld studied the effect of CCK-4 on 
himself and his colleague Thue Schwartz. Intravenous injection of CCK-4 
provoked a fast-onset anxiety reaction that was accompanied by palpitations, 
sweating, and faintfulness (Rehfeld, 1992). Early electrophysiological studies 
revealed that CCK-8 can produce marked excitation of the cortical and 
hippocampal neurones — an effect that can be antagonised by benzodiazepine 
anxiolytics (Bradwejn and de Montigny, 1984; Bradwejn and de Montigny, 
1985). Then intensive research towards the understanding of CCK functions in 
the mechanisms of anxiety started. The data obtained from the human studies 
established the panicogenic properties of CCK-4 (de Montigny, 1989; 
Bradwejn et a l, 1990). This effect of CCK-4 is clearly mediated via the CCKB 
receptor subtype (Bradwejn et al., 1994; Lines et al., 1995). Moreover, patients 
suffering from the panic disorder are more susceptible to the emotional action 
of CCK-4 compared to healthy volunteers (Bradwejn et a l, 1991; van Megen et 
al., 1994). Despite the string similarity of CCK-4-induced panic-like attacks to 
the natural ones, the CCKB antagonists have not yet been proven to be the 
effective drugs for the treatment of anxiety disorders (Kramer et a l, 1995).
Studies on rats have also revealed the anxiogenic-like effect of CCK 
agonists in the ethological and conditioned models (Harro et al., 1990; Harro 
and Vasar, 1991; Rex et al., 1994). Different anxiogenic manipulations and 
stressful events increased the levels of CCK-4 in a number of brain areas of rat, 
including the frontal cortex (Pavlasevic et al., 1993). Harro and co-workers 
(1990) described that diazepam withdrawal anxiety was associated with the 
increased density of CCK receptors in the rat frontal cortex and hippocampus. 
The anxiogenic ß-carboline FG-7142 also upregulated the number of CCK
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binding sites in the frontal cortex (Harro et a l, 1990) and increased the content 
of prepro-CCK mRNA in the limbic structures (Pratt and Brett, 1995). 
Similarly, the social isolation induced anxiogenic-like action and elevated the 
number of CCK receptors in the frontal cortex (Vasar et al., 1993).
Several early studies have found that CCKB receptor antagonist L-365,260 
(1 and 10 |ig/kg) and CI-988 (0.01 and 1.0 mg/kg) display the anxiolytic-like 
action in the rat plus-maze paradigm (Hughes et al., 1990; Ravard et al., 1990). 
The dose-effect curve for L-365,260 was bell-shaped with loss of activity at 
doses above 10 M-g/kg (Chopin and Briley, 1993). However, some studies have 
described the anxiolytic-like effect of CCKA antagonist devazepide (Hendrie et 
al., 1993b). Although early studies with the selective and non-peptide CCK 
antagonists revealed the anxiolytic potential, the further experiments failed to 
show consistent anxiolytic-like activity of CCKB antagonists (Dawson et al., 
1995; Johnson and Rodgers, 1996). Lack of anxiolytic-like profile of the CCKB 
antagonists seems to be related to the experimental paradigm. In the condi­
tioned models (fear-potentiated startle, punished drinking, etc) different CCKB 
antagonists (L-365,260; CI-988; L-740093) are not effective against the behav­
ioural suppression (Dawson et al., 1994; Rodgers et al., 1997). However, 
CCK antagonists display the anxiolytic-like profile in the ethological or uncon­
ditioned models (the elevated plus-maze and the light/dark compartment test) 
(Costall et al., 1991; Chopin and Briley, 1993). These tests are based on the 
natural neophobia of animals towards the unfamiliar environment, which 
invariably include areas of relative safety. These tests are generally believed to 
be more sensitive for non-benzodiazepine anxiolytic drugs (including CCK 
antagonists) (Rodgers et a l, 1997). Moreover, the activation of peptide 
neurotransmission occurs only in the case of bursting or high-frequency neu­
ronal activity. Therefore, the peptide antagonists itself should not necessarily 
show any effect under normal tonic conditions (Harro et a l, 1995b).
The systemically administered CCK produces a large and immediate in­
crease in plasma levels of the adrenocorticotropic hormone (ACTH) and 
corticosterone in rat and man (Spath-Schwalbe et al., 1988; Kamilaris et al., 
1992; Biro et a l, 1993). CCK stimulates the release of corticotropin-releasing 
hormone (CRH) from the cultured hypothalamic neurones and also increases 
the release of ACTH in vitro (Reisine and Jensen, 1986). The possible site for 
the interaction between CCK and CRH seems to be in the paraventricular 
nucleus, where the co-localisation of two neuropeptides is established (Mezey 
et al., 1985). These findings suggest that CCK can act at the circumventricular 
sites of the hypothalamus and activate the hypothalamic-pituitary-adrenal 
(HPA) axis. In humans, the administration of pentagastrin (CCK-5) is accompa­
nied by the two-fold elevation of the ACTH levels (Abelson et a l, 1994). Also, 
studies with animals confirmed the raised plasma corticosterone levels in rats 
after exposure to the elevated plus-maze or to the cat odour (File et a l, 1993;
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File et al., 1994). On the other hand, it has been shown that several psychiatric 
disorders exhibit seasonal variability. Many reports have confirmed increase in 
the incidence of panic attacks and incidence of suicides in summer (Maes et al., 
1993; Marriott et al., 1994). Moreover, circannual endogenous rhythm in the 
function of 5-HT activity exists (Egrise et al., 1986; Nagayama and Lu, 1998). 
Therefore, the possible seasonal variation in the exploratory activity of the rats 
and its relation to the changes in the CCK-ergic neuronal circuits was studied.
2.3. CCK-opioid interactions
At the beginning of the eighties two studies described the ability of CCK-8 to 
antagonise opioid-induced analgesia (Faris et al., 1983; Itoh et al., 1985). Since 
then there has been a considerable interest in exploring the possibility that CCK 
may act as the endogenous antagonist of opioid peptides (Faris, 1985a; Faris, 
1985b). In addition, the distribution of CCK peptides in the brain matches that 
of opioid peptides — enkephalin, ß -endorphin, and dynorphin (Stengaard- 
Pedersen and Larsson, 1981; Baber et al., 1989; Skinner et a l, 1997). Despite 
the numerous studies the actual role of CCKA or CCKB receptors in opioid 
analgesia remains to be established (Dourish et al., 1990; Benedetti et al., 1997; 
Benedetti, 1997). The ability of CCKB antagonists to prevent the development 
of opioid tolerance and dependence is shown (Idanpaan-Heikkila et al., 1997; 
Kayser et al., 1998). There is also evidence that CCKA receptors are responsi­
ble for the rewarding properties of morphine, whereas CCKB receptors 
modulate the analgesic activity of morphine (Singh et al., 1996). Interestingly, 
the increased number of CCK receptors in the supraoptic nucleus after the 
chronic morphine administration is described, suggesting a role of increased 
sensitivity to the endogenous CCK in the development of tolerance to the 
analgesic effect of morphine (Munro et al., 1998). The anatomical substrate for 
CCK-opioid interplay is not definite as yet. A clear anti-opioid action of CCK 
is described on the neuronal level in the spinal cord (Suh and Tseng, 1990). 
However, the supraspinal structures, particularly periaqueductal grey, are also 
involved (Hendrie et al., 1989a; Dourish, 1992). The cellular mechanisms for 
that interaction are unclear. The electrophysiological studies demonstrated that 
CCK diminished morphine-induced inhibition of dorsal horn neuronal firing in 
response to the painful stimuli, whereas CCK antibodies and antagonists 
enhanced it (Suberg et al., 1985; Suberg and Watkins, 1987). Otherwise, CCK 
has been described to increase the level of intracellular calcium in the 
presynaptic terminal by the mobilisation from the intracellular stores, thus 
antagonising the suppression of the increase of internal calcium by opioids 
(Wang et al., 1992).
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However, only few studies have been conducted to explore the role of 
opioid peptides in CCK-induced behavioural effects. The importance of opioid 
peptides has been established in the regulation of exploratory behaviour. Motta 
and Brandao (1993) have shown that the systemic administration of morphine 
at low doses or its injection into the dorsal periaqueductal grey induced 
anxiolytic-like action in the elevated plus-maze. Moreover, the environmental 
stimuli seem to be important in the regulation of tone of the endogenous opioid 
system. Stressful stimuli can increase the release of opioid peptides (Rodgers 
and Deacon, 1979). The CCK antagonists devazepide and L-365,260 potentiate 
morphine antinociception only in a novel but not in a familiar environment 
(Lavigne et a l, 1992). According to a recent study, ц-opioid receptors play a 
crucial role in the discriminative properties of CCK (Riley and Melton, 1997).
2.4. CCK-serotonin (5-HT) interactions
Several preclinical and clinical studies have shown the involvement of interplay 
between 5-HT and CCK in the development of anxiety. The anatomical 
substrate for this interaction seems to be the pathway arising from the raphe 
nucleus (median raphe nucleus) and terminating in the limbic and prefrontal 
cortical structures (Andrews et al., 1997; Coplan and Lydiard, 1998). CCK-8 
excites 5-HT neurones in the dorsal raphe nucleus (Boden et al., 1991; Boden 
and Woodruff, 1994) and facilitates 5-HT release in the rat hypothalamus 
(Voigt et al., 1998). The exposure of animals to a novel aversive environment 
(e.g. the elevated plus-maze) induces the cortical and hippocampal release of 
5-HT, and this effect can be potentiated by CCK-4 (File et al., 1993; Rex et al., 
1994; Rex and Fink, 1998). The administration of 5-HTiA receptor agonist 
8-OHDPAT or CCKB receptor antagonist L-365, 260 can reverse this effect of 
CCK-4 (Rex et al., 1994; Rex and Fink, 1998). Selective 5-HT re-uptake 
inhibitors (SSRIs) have been found to reduce the anxiolytic-like action induced 
by CCK receptor antagonists (Bickerdike et a l, 1994).
The changes in 5-HT neurotransmission seem to be crucial in mediating of 
behavioural reactions to the unpleasant events. However, the neuroanatomical 
substrate is not established as yet. Several studies support the importance of 
hippocampal 5-HT release as the trigger of anxiogenic-like behaviour (Andrews 
and File, 1993). Other studies have been paid main attention to the cortical 
changes and found 5-HT release in that site also plays a role (Rex et al., 1993). 
Also, it is established that anxiogenic stimuli influence differently 5-HT 
metabolism in the different brain regions. The exposure of rats to the cat odour 
and diazepam withdrawal increased the cortical 5-HT and 5-HIAA levels. 
However, in the hippocampus only diazepam withdrawal increased content of
16
5-HT, whereas the cat odour exposure decreased the levels of 5-HT and 
5-HIAA (Andrews et a l,  1993).
However, most experiments have studied the role of 5-HT in the action of 
drugs influencing CCK-ergic transmission, whereas the opposite interaction has 
remained out of scope. Nevertheless, few studies have been conducted in this 
field and it has been shown that 5-HT can increase the release of CCK in the 
cerebral cortex and nucleus accumbens (Raiteri et a l, 1993). The acute 
administration of alaproclate, the selective 5-HT reuptake inhibitor (SSRI), 
significantly elevates the levels of CCK in the cingulate cortex and 
periaqueductal grey (Rosen et a l, 1995). Fluoxetine, the 5-HT reuptake 
inhibitor, dose-dependently reduces the exploratory behaviour of rats in the 
elevated plus-maze (Handley and McBlane, 1993). The anxiogenic-like effect 
of drugs, increasing the content of 5-HT in the brain, is also supported by the 
human data. Den Boer and Westenberg (1996) have found that acute 
administration of 5-HT reuptake inhibitors can increase anxiety in patients 
suffering from anxiety disorders. On the other hand, the chronic treatment (for 
8 weeks) with SSRI-s results in the decreased sensitivity to the anxiogenic 
properties of CCK-4 in panic disorder patients (Boyer, 1993; van Megen et a l, 
1997). Therefore, one aim of our study was to verify the CCK-5-HT interaction 
in the action of SSRIs (paroxetine) and in the development of exploratory 
behaviour.
17
3. OBJECTIVES
According to the recent investigations the role of CCK in animal models of 
anxiety remains to be controversial. There are studies supporting the role of 
CCK, whereas the others do not confirm that. The background of these 
inconsistencies is not clear and therefore will need further clarification. In the 
present study a stress was put on the environmental factors influencing the level 
of anxiety in rats and affecting the response of animals to the anxiogenic action 
of CCK. According to these studies the conditions were selected where the 
anxiogenic action of CCK agonists was the strongest. In these particular 
conditions the interaction of CCK with endopioid mechanisms and 5-HT was 
explored.
The more specific purposes of our study were as follows:
1. To explore the influence of pre-experimental stress on the action of 
CCK agonist and the seasonal variations of exploratory activity. For
these aims two pre-experimental procedures — handling and isolation were 
used. We studied the action of caerulein, an unspecific CCK agonist, in the 
elevated plus-maze after different pre-test manipulations. As the occurrence 
of panic attacks has been shown to be higher in summer besides to winter, 
we compared also the exploratory activity of rats and CCK neurotransmis­
sion in summer and in winter.
2. To reveal the biochemical mechanisms those underlie the individual 
differences of exploratory behaviour of rats in the elevated plus-maze.
The rats were selected according to exploratory behaviour in the ele­
vated plus-maze. The radioligand binding and hormonal studies were 
performed to establish a role of CCK in the individual differences of 
exploratory behaviour.
3. To establish the role and nature of the interplay between CCK and 
endopioid mechanisms in the regulation of anxiety. For this goal agonists 
and antagonists for CCK and opioid receptors were combined, and their 
action in the elevated plus-maze was studied.
4. To study the involvement of 5-HT-CCK interaction in the regulation of 
anxiety. For that purposes we studied the influence of paroxetine, a 
selective serotonin reuptake inhibitor (SSRI), on the exploratory behaviour 
and CCK neurotransmission.
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4. MATERIALS AND METHODS
4.1. Animals
Male Wistar rats (Han/Kuo: WIST) were obtained from the National Animal 
Centre, Kuopio, Finland. The animals weighing 200-360 g were used for 
experiments. The animals were housed four per cage under artificial conditions 
with free access to water and food pellets. The animal house had con­
trolled temperature at 20°C±2°C and 12 h light/dark illumination cycle (lights 
on at 7:00). At least one hour before an experiment the animals were moved 
with their home cages to the experimental room.
4.2. Drugs
Caerulein (CCK-like decapeptide, Sigma Co), BOC-CCK-4 (N-tert-Butoxy- 
carbonyl-CCK-4, Sigma Co), morphine sulphate (Boehringer-Ingelheim), 
naloxone HC1 (Sigma Co), paroxetine (Smith Kline and Beecham, U.K.) were 
dissolved in physiological saline (0.9% sodium chloride solution). L-365,260 
[(3R(+)-N-2,3-dihydo-1 -methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepine)-3-y 1)- 
N1-(3-methylphenyl)urea] Merck Sharp & Dohme], L-364,718 or MK-329 
or devazepide (3S(-)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodi- 
azepine-3-yl)-lH-indole-2-carboxamide, Merck Sharp & Dohme), LY 288,513 
[trans-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-1 -pyrazolidinecarboxamide, Ely 
Lilly & Co, U.S.A.] and diazepam (Sigma, U.S.A.) were suspended in 1% 
Tween-80 (Sigma Co) solution in saline.
Caerulein, BOC-CCK-4 and morphine were administered subcutaneously, 
whereas naloxone, paroxetine, L-365,260 and LY 288,513 were given intrape- 
ritoneally.
For radioligand binding experiments raclopride (S-3,5-dichloro-N[(l-ethyl- 
2-pyrrolidinyl)methyl]-6-methoxysalicylamide tartrate, Astra AB, Sweden), and 
ketanserin (Janssen) were dissolved in saline. Clonazepam (Hoffman La Roche, 
Switzerland) was dissolved in ethanol and therefore diluted in the incubation 
buffer, where the final concentration of ethanol was about 0.05%.
The radioligands [Propionyl-3H]-propionylated-CCK-8-sulphated ([3H]p 
CCK-8), [3H]-spiperone and [3H]-flunitrazepam were obtained from Amersham 
Radiochemicals (U.K.). The other chemicals for radioligand binding stud­
ies (caerulein, HEPES (N-[2-hydroxyethyl]piperazine-N’-[-2-ethane-sulfonic 
acid]), NaCl, MgCb, KC1 and EDTA [ethylenediamine-tetraacetic acid]) were 
purchased from Sigma (U.S.A.).
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4.3. Behavioural studies
4.3.1. Pre-experimental manipulations
The animals were brought into the experimental room 1 hour before the 
experiment. The rats were handling-naive and were not adapted to the experi­
mental situation, if not specified otherwise. Each rat was used only once. All 
experiments were carried out between 12:00 to 19:00.
To study the effects of pre-experimental manipulations on the exploratory 
behaviour and anxiogenic-like effect of CCK in the elevated plus-maze, an 
experiment was performed in November and December. Before the experiment 
handling and brief isolation were combined as two different stressors. The rats 
were divided into four different groups. Two groups of rats were handled in the 
experimental room on three consecutive days (twice daily) before the 
experiment. The other two groups of animals were brought to the experimental 
room immediately before the beginning of the experiment. The handled and 
non-handled rats were divided into two groups after the injection of caerulein 
(5 |ig/kg s.c., Sigma), an agonist of CCK receptors. Caerulein or saline was 
injected 15 min before the beginning of the plus-maze study. One half of 
animals was isolated after the injection, whereas the other half was placed back 
into the home-cage. The action of the CCKB antagonist L-365,260 (1- 
100 |ng/kg i.p., Merck Sharp & Dohme) and CCKA antagonist devazepide 
(1-100 |ig/kg i.p., Merck Sharp & Dohme) on the anxiogenic-like action of 
caerulein was also studied. CCK antagonists or vehicle (2% Tween-85 in 
physiological saline) were injected 30 min before the plus-maze exposure.
In the second half of the experiment, the possible seasonal differences in the 
exploratory activity of rats were studied. Two studies were performed — one 
study was conducted at the beginning of July 1993 (summer) and the other one 
in late November of 1994 (winter). This study was performed in 40 handling- 
naive rats (in both experiments). The animals were decapitated immediately 
after the plus-maze exposure, and the blood and brain samples were taken for 
the neurohormonal studies.
4.3.2. Elevated plus-maze
The method initially suggested by Handley and Mithani (1984) for the measure­
ment of exploratory activity was employed with some modifications (Pellow et 
al., 1985). The apparatus consisted of two opposite open arms (50x10 cm) 
without side walls and two enclosed arms (50x10x40 cm) with side walls and 
an end wall, extending from a central square (10x10 cm). The maze was 
elevated to the height of 75 cm, and placed in a lit room. During a 5-min 
observation session an observer took the following measures:
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1) latency of the first open part entry;
2) time spent in exploring the open part and open arms of plus-maze;
3) number of closed and open arm entries;
4) number of lines crossed in the open part;
5) ratio between open and total arm entries (also % open entries).
At the beginning of the experiment an animal was placed into the centre of the 
plus-maze, facing towards the closed arm. An arm entry was counted only when 
all four limbs of the rat were within the given arm. Time spent in open arms, 
number of open arm entries and the ratio between open and total arm entries are 
the “classical” measures of anxiety in the elevated plus-maze (Rodgers and 
Johnson, 1995). By contrast, the number of closed arm entries and the number 
of line crossings are the measures reflecting the locomotor activity of rats 
(Rodgers and Johnson, 1995; Rodgers et al., 1997).
4.3.3. Motility test
Exploratory activity of rats was measured by means of photoelectric motility 
boxes (448x448x450 mm) connected to a computer (TSE, Technical & 
Scientific Equipment GmbH, Germany). Animals, naive to the test situation 
were placed singly into the box. Time in exploration (sec), distance of explora­
tion (in metres), number and duration of rearing were registered at 5-min 
intervals during the 15-min observation period.
4.4. Radioligand binding studies
4.4.1. Preparation of brain samples
After decapitation the brains were quickly dissected on ice according to the 
method of Glowinski and Iversen (1966). The binding studies for CCK 
receptors were performed in the frontal cortex (also containing the anterior 
cingulate and frontoparietal cortex) and hippocampus. Benzodiazepine and 
5-HT receptors were analysed in the frontal cortex (contains the anterior 
cingulate and frontoparietal cortex). For the study of dopamine receptors the 
striatum was used. These brain structures were selected according to the 
previous studies since the most prominent changes due to the exploratory 
behaviour have occurred in these brain regions (File et al., 1993; Rex et al., 
1994; Pratt and Brett, 1995). Brain tissues were homogenised in 20 volumes of 
ice-cold 50 mM Tris-HCl (pH 7.4 at 4°C) using a Potter-S glass-teflon 
homogeniser (1000 rpm, 12 passes). The membranes were washed twice in the 
same buffer by centrifugation (48 OOOxg for 20 min) and resuspension.
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Thereafter brain samples were resuspended in the appropriate incubation buffer 
at a concentration of 10 mg wet weight/ml.
4.4.2. [Propionyl-3H]-propionylated-CCK-8-sulphated binding 
for CCK receptors
After the last centrifugation, the crude brain membranes were homogenised in 
HEPES buffer (10 mM HEPES; 130 mM NaCl; 5 mM KCl; 1 mM MgCl2;
1 mM EDTA; pH 6.5 adjusted with 1 N NaOH) containing bovine serum 
albumin (0.5 mg/ml). The parameters of CCK receptors were determined in the 
presence of 0.05-2.4 nM [3H]pCCK-8 (specific activity 79 Ci/mmol) at 23°C in 
a total incubation volume of 0.5 ml. Caerulein (100 nM) was added to 
determine the non-specific binding. The incubation was terminated after 
120 min by the rapid filtration over Whatman GF/B filters pre-soaked with the 
bovine serum albumin (0.5 mg/ml). The filters were washed with 3x3 ml of ice- 
cold HEPES buffer. In a separate study paroxetine (0.01-1 mM) was added to 
the incubation medium to reveal the possible direct interaction of paroxetine 
with CCK binding sites in the frontal cortex.
4.4.3. [3H]-spiperone binding for serotonin (5-HT2a) receptors
After the final washing the crude brain membranes were homogenised in the 
incubation buffer consisting of 50 mM Tris-HCl, 120 mM NaCl, 5 mM KC1,
2 mM CaCl2, 1 mM MgCl2 (pH 7.4). [3H]-spiperone (specific activity 
105 Ci/mmol) at final concentrations 0.06-2 nM was incubated 30 min at 37°C 
with the membrane preparation in 0.5 ml of the reaction volume. Non-specific 
binding was determined in the presence of 1 (iM ketanserin. Incubation was 
stopped by the rapid filtration through Whatman GF/B glass fibre filters (pre­
soaked with 0.05% polyethylenimine).
4.4.4. [3H]-spiperone binding for dopamine (D2) receptors
After the washing the crude brain membranes were homogenised in the 
incubation buffer consisting of 50 mM Tris-HCl, 120 mM NaCl, 5 mM KC1, 
2mM  CaCl2, 1 mM MgCl2 (pH 7.4). [3H]-spiperone (specific activity 
105 Ci/mmol) at final concentrations 0.06-2 nM was added to the tissue 
preparation. Nonspecific binding was determined in the presence of 1 |nM 
raclopride. The incubation was carried out in a total volume of 0.5 ml for 
30 min at 37°C and was terminated by the rapid filtration over pre-soaked
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Whatman GF/B filters and the filters were washed 3x3 ml with ice-cold 
incubation buffer.
4.4.5. [3H]-flunitrazepam binding for benzodiazepine receptors
The pellets were homogenised in Tris-HCl buffer (50 mM Tris-HCl, 120 mM 
NaCl, 5 mM KC1, 2 mM CaCl2, 1 mM MgCl2, pH 7.4). The membranes were 
incubated in the presence of 0.25-16 nM N-methyl-[3H]-flunitrazepam (specific 
activity 90 Ci/mmol) at 4°C in a total volume of 0.5 ml in the presence or 
absence of unlabelled clonazepam (1 (iM) to determine non-specific binding. 
Incubation was terminated after 60 minutes by rapid filtration over Whatman 
GF/B filters, thereafter washed with 9 ml ice-cold buffer.
The filters were dried and left overnight in Wallac High Safe HI scintillation 
cocktail. Radioactivity was assayed by liquid scintillation spectrometry (Wallac 
ß-scintillation counter) at 50 per cent efficiency level. The protein content was 
measured according to a dye-binding assay (Bradford, 1976). Saturation curves 
were analysed using non-linear least squares regression (Leatherbarrow, 1987).
4.5. Hormonal studies
In all cases truncal blood was collected, serum was separated by centrifugation 
and samples were stored at -20°C until prolactin (PRL), thyrotropin (TSH) and 
growth hormone (GH) concentrations were determined from duplicate samples 
(0.1 ml) by specific radioimmunoassays. The rat PRL, TSH and GH kits were 
gifts from NIH. PRL results are expressed in ng/ml of NTODK-rPRL-RP-2 
standard. TSH data are expressed in ng/ml of NIDDK-TSH-RP-2 standard. 
GH results are expressed in ng/ml of NIDDK-GH-RP-2 standard. The intra­
assay coefficient of variation was less than 15%.
4.6. Statistical analysis
The analysis of data was performed by means of the Statistica for Windows 
(StatSoft Inc., USA) software. The results are expressed as mean val­
ues ± S.E.M. Behavioural and hormonal data were analysed by one-way 
analysis of variance (ANOVA). Post hoc comparisons were performed by 
means of Newman-Keuls or Tukey HSD tests. The data of radioligand-binding 
experiments were assayed by means of Student’s r-test.
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5. RESULTS AND DISCUSSION
5.1. Pre-experimental stress and seasonal variations 
in the action of CCK (paper V)
Nonspecific CCK agonist caerulein (5 |J,g/kg) caused the strongest action in 
animals brought to the experimental room immediately before the experiment 
(not subjected to pre-experimental handling) and kept in isolation after the 
administration of caerulein (Figure 1). The effect of CCK agonist was antago­
nised by L-365,260 (1-100 |U.g/kg), an antagonist of CCKB receptors, in a dose- 
dependent manner with a statistically significant effect at a dose of 100 |ig/kg 
(Figure 2). One hundred |lg/kg of devazepide, an antagonist of CCKA receptors, 
was also effective in reversing the anxiogenic-like action of caerulein in 
stressed animals, but this effect was not as clear as in the case of L-365,260. In 
the experiments where CCK antagonists were given as a single treatment, only
10 (Xg/kg of L-365,260 induced anxiolytic-like action, whereas devazepide was 
without any effect. One and 100 Jig/kg of L-365,260 were without any signifi­
cant influence (Figure 2).
This study revealed a clear relation between the anti-exploratory effect of 
caerulein and pre-experimental stress. This finding is in good accordance with 
the previous studies showing the presence of an anxiogenic-like action of 
CCK only in a novel environment (Dauge et al., 1989). Neurochemically, 
CCK-4 potentiated an increase in the 5-HT levels in the lateral prefrontal cortex 
only during the exposure of guinea pigs to the elevated plus-maze, but it had no 
effect in the animals that remained in their home-cage (Rex and Fink, 1998). 
Moreover, CCK antagonised morphine-induced analgesia in rats in novel, but 
not in familiar, experimental conditions (Wiertelak et al., 1992). Accordingly, 
caerulein seems to potentiate neophobia in rats. However, novelty is not the 
only factor determining the action of caerulein in the plus-maze. The keeping of 
rats in social isolation after the injection of CCK also contributes to the action 
of caerulein. It is likely that the social isolation of rats may sensitise the 
animals to the anxiogenic-like effect of caerulein. The effective dose of agonist 
and behavioural patterns after CCK challenge depend on baseline anxiety of the 
animal. It has been shown that 10-50 times lower doses of caerulein and 
pentagastrin are anxiogenic in rats and mice housed under stressful over­
crowded conditions (Harro et al., 1995b). In our previous studies we have 
found that the social isolation of rats for 7 days induced anxiety in animals, but 
it also increased the density of CCK but not benzodiazepine receptors in the 
frontal cortex (Vasar et al., 1993). According to our recent study CCK agonists 
produced the anxiogenic-like action only in rats not acclimatised to the 
experimental situation (Vasar et al., 1997). It has been shown that pre-
24
experimental stress also increases the effectiveness of anxiolytic drugs in the 
plus-maze showing that the endogenous tone is an important factor in studying 
anxiety in rodents (Rodgers et al., 1997). It is worthy to point out that patients 
suffering from anxiety disorders are also more sensitive to CCK-4- and 
pentagastrin-induced panic attacks than healthy volunteers (Bradwejn et al., 
1994; Shlik et al., 1997). The characteristic feature of anxiety disorders is the 
increased serum level of stress hormones (ACTH, cortisol) (Abelson et al., 
1994; Arborelius et al., 1999). Collectively, the level of pre-experimental stress 
is a factor that determines the potential response both in animals and in man to 
the anxiogenic-like action of CCK agonists.
I I Handling, no isolation 
■ ■  Handling, isolation 
V/Л  No handling, no isolation 
L \\\l No handling, isolation
Saline Caerulein
Figure 1. The effect of pre-experimental handling and isolation on the anti-exploratory 
action of caerulein measured in the elevated plus-maze. * —  p<0.05 (compared to the 
respective saline group, the Newman-Keuls test after significant one-way ANOVA).
The potentiation of neophobia induced by caerulein was dose-dependently 
antagonised by the CCK antagonists L-365,260 and devazepide. The nearly 
equal potency of L-365,260 and devazepide against caerulein makes it unlikely 
that this effect of CCK antagonists may be mediated primarily via CCKA 
receptors. This statement is based on the knowledge that devazepide has very 
high affinity for CCKA, but it is relatively non-selective and has much better 
penetration, compared to L-365,260, into the brain (Hargreaves and Lin, 1992). 
CCKB receptors are likely targets for the anxiogenic-like action of caerulein as 
100 ng/kg of devazepide interacts also with this subtype (Woodruff and 
Hughes, 1991). This is in an agreement with the previous studies showing the 
key role of CCKb receptors in CCK-induced anxiety both in the human and 
animal studies (Harro et al., 1995b). The single treatment with L-365,260, but 
not with devazepide, induced the anxiolytic-like action in rats. However, the 
action of L-365,260 was not dose-dependent since only one dose of the CCKB
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receptor antagonist (10 |ig/kg) was effective, and the lower and higher doses 
did not change the exploratory behaviour of rats. The U-shape action of 
L-365,260 has been also established in our previous studies (Harro and Vasar, 
1991), but the background of this peculiar action remains to be established.
Vehicle Upg/kg UOpg/kg L100pg/kg Veh+ V«h+ Lt+ 110+ 1100+ 
sil c u r caer cwr си г
Figure 2. The effect of L-365,260 on the exploratory behaviour of rats in the plus-maze 
and on the anxiogenic-like action of caerulein and upon the exploratory behaviour in the 
elevated plus-maze. * —  p<0.05 (compared to vehicle or vehicle + saline treated, 
Newman-Keuls after significant ANOVA); + — p<0.05 (compared to vehicle + 
caerulein treated, Newman-Keuls after significant ANOVA).
The second part of this study established seasonal fluctuations in the explora­
tory behaviour. Indeed, the exploratory activity of rats was much lower in July 
compared to the study performed in November (Table 2). The animals with a 
low exploratory activity displayed an increased number of CCK receptors in the 
frontal cortex and hippocampus and elevated density of 5-HT receptors in the 
frontal cortex (Figure 3). Also, the serum levels of the growth hormone were 
higher in July compared to November (Figure 3).
Table 2. Comparison of the results of two distinct experiments, performed in July and 
November —  plus-maze exploration
Plus-maze parameters July November
Time in open part (sec) 46 ± 6 91 ±6*
Number of open arm enrtries 0.2 ±0.1 1.3 ±0.3*
Time in open arm (sec) 4 ± 2 14 ± 3*
Number of total arm entries 3.1 ±0 .3 7.8 ±0.6*
% open entries 4 ± 2 19 ± 4*
* — p<0.05 (Student’s Mest).
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Figure 3. Comparison of the results of two experiments performed in July and in 
November: CCK and 5-HT receptors in the brain and serum levels of growth hormone. 
* — p<0.05 Student’s t-test.
The present study provides a strong evidence of seasonal variations in the 
exploratory activity of rats. The comparison of exploratory activity of rats in 
two experiments conducted in July (summer) and in November (winter) 
revealed a clear difference. The exploratory activity of rats was much lower in 
summer compared to winter. Harro and others (1997) obtained similar results 
showing significant variation in the exploratory activity of rats in two studies, 
in November and in June. Moreover, it is important to stress that the anxio­
genic-like action of caerulein is much weaker in summer compared to the 
studies performed in winter (our unpublished data). This was the reason why 
the influence of pre-experimental stress to the anxiogenic-like action of CCK 
agonist was studied in winter but not in summer. Also, these data are interesting 
in the light of recent reports describing significantly higher summer incidence 
in the occurrence of the first panic attack compared to winter (Cameron, 1989;
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Lepine et a l, 1991; Marriott et al., 1994). The hypothetical reason for such 
seasonality is the increased activity of people that leads to the overcrowding of 
public places (Lelliott et al., 1989). In rats the increased level of anxiety in 
summer could be explained by the higher pressure from the surrounding nature 
since in summer the number of potential predators is much higher than in 
winter when life in nature apparently slows down. This statement is supported 
by the recent findings showing the seasonal fluctuations in the serum levels of 
ACTH in the sand rat with the maximum concentration during the late spring 
and summer (Amirat and Brudieux, 1993).
In summer the rats also had significantly increased levels of the growth 
hormone, whereas the levels of prolactin and thyrotropin remained unchanged. 
A recent study has established that healthy subjects respond to CCK-4 
challenge with an increased level of the growth hormone, which was higher in 
those who panicked after CCK-4 than in non-panickers (Koszycki et al., 1998). 
This finding is also in line with our study that neither the exposure of rats to the 
plus-maze nor distinctive exploratory activity correlated with the serum levels 
of the anterior pituitary hormone prolactin or thyrotropin (see part 5.2). Only 
the concentrations of the growth hormone were significantly different in the 
rats selected according to the exploratory behaviour. Namely, the animals with 
a higher exploratory activity had markedly lower levels of the growth hormone 
compared to the animals with a low activity. 5-HT stimulates the release of the 
growth hormone in response to stress (Chamey et a l, 1987). Moreover, the 
activation of CCKB receptors has been shown to increase the baseline release 
on the growth hormone (Männistö et a l, 1994; Peuranen et a l, 1994). There­
fore, the enhanced levels of the growth hormone in animals in summer might be 
caused by the increased activity of 5-HT and CCK in the brain.
The reduced exploratory activity of rats in summer appears to be related to 
the increased number of CCK receptors in the frontal cortex and hippocampus. 
Harro and others (1997) have reached the same results that in June, when the 
exploratory activity was lower, the density of CCK receptors was higher in the 
frontal cortex, hippocampus, and striatum but not in the hypothalamus. 
Moreover, in summer the content of different CCK fragments (CCK-8s, 
CCK-8us, CCK-4, CCK-5) in the frontal cortex and in the hippocampus was 
much higher compared to the experiments conducted in November. In the light 
of these data, it is likely that the tone of CCK-ergic transmission may be higher 
in summer compared to winter. This could be a possible explanation why the 
anxiogenic-like action of caerulein is much weaker in summer since CCK 
receptors seem to be occupied by the endogenous ligand. In addition, we have 
noted an increased density of serotonin 5-HT2 receptors in the frontal cortex of 
rats having a decreased exploratory activity. By contrast, the number of 
dopamine D2 receptors in the striatum remained unchanged. Accordingly, 
increased susceptibility to the unpleasant events in rats seems to be related to 
the increased density of CCK and 5-HT2 receptors in the forebrain.
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Taken together, different pre-experimental manipulations and seasonal 
variations could be the reason for inconsistent findings in studies with 
CCK-ergic compounds. Behavioural validation and unifying of the test condi­
tions before the ethological studies are needed to reduce the variations.
In conclusion, the anxiogenic-like action of caerulein was dependent on pre- 
experimental stress in animals. The CCK agonist caused the strongest action in 
rats not adapted to the experimental conditions. In addition, seasonal variations 
of exploratory activity were revealed in the present study. The rats were more 
active in winter than in summer. The reduced exploratory activity of rats was 
apparently related to the increased density of CCK and 5-HT2 receptors in the 
brain. Also, the levels of the growth hormone were markedly higher in animals 
displaying reduced exploratory activity. Therefore, the lower exploratory 
activity in summer could be caused by the activation of CCK-ergic and 5-HT- 
ergic neurotransmission.
5.2. Relation of exploratory behaviour to neurochemical changes
(paper I)
Forty-five male Wistar rats were selected according to their exploratory 
behaviour in the elevated plus-maze. They were separated as follows: 
“anxious” rats (7 animals) with low exploratory activity, “intermediate” rats 
(30 animals) with intermediate exploratory activity, and “non-anxious” rats 
(8 animals) having high exploratory activity (Table 3). In “anxious” rats the 
affinity of 5-HT2a receptors was lower compared to home-cage controls and 
“non-anxious” rats. Also, the number of CCK receptors in the hippocampus 
was elevated in the “anxious” rats compared to home-cage controls (Figure 4). 
Additionally, the blood levels of the growth hormone (GH) were significantly 
lower in “non-anxious” rats compared to “anxious” counterparts (Figure 4).
Table 3. Selection of rats according to exploratory behavior in the elevated plus-maze 
(mean values ± S.E.M.)
Behavioural parameters “Anxious”
N=8
“Intermediate”
N=30
“Non-anxious”
N=7
Time spent in central square (sec) 0.5±0.3 69±4a 98±10ab
Time spent in open arm (sec) 0 8±3 38±8a,b
Number of open arm entries 0 0.6±0.2 4.0±0.7a,b
Number of closed arm entries 1.0±0 5.5±0.5a 10.4±0.8a,b
Ratio open arm entries/closed arm 
entries
0 0.10±0.03 0.38±0.05a,b
a — p<0.05 (compared to “anxious” animals, the Newman-Keuls test after significant 
one-way ANOVA); b — p<0.05 (compared to the “intermediate” group).
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Figure 4. Parameters of serotonin 5 -H T 2a and CCK receptors and the serum levels of 
the growth hormone in selected rats. * —  p<0.05 (compared to home-cage controls, the 
Newman-Keuls test after significant one-way ANOVA); + — p<0.05 (compared to 
“anxious”).
These behavioural findings are in agreement with the previous experiments 
confirming the significant variability of exploratory behaviour of rats in the 
elevated plus-maze (Harro et al., 1990; Rägo et al., 1991). Among the 45 
selected rats we established a subgroup of animals eagerly exploring the open
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arms. The open arms were considered to be the most aversive parts of the plus- 
maze (Pellow et al., 1985). Moreover, a recent study of factor analysis 
behaviour (Rodgers and Johnson, 1995). These “non-anxious” rats performed 
revealed a positive correlation between open arm entries and anxiolytic-like 
three or more open arm entries per session. On the other hand, the other 
subgroup of rats (“anxious”) did not leave the enclosed arms at all. It is worthy 
to note that these “anxious” animals made several unsuccessful attempts to 
enter from the enclosed arm into the central square reflecting the increased risk 
assessment behaviour. Accordingly, the central square located between the 
opened and enclosed arms is too aversive for “anxious” rats to explore. The 
exploratory behaviour of the “intermediate” group represents the mean explora­
tory activity of the whole population. Their behavioural activity was mainly 
restricted to the central square.
The radioligand binding data are somewhat different from the previously 
published results. Harro et al. (1990) have found that “anxious” animals have a 
significantly increased density of CCK receptors in the frontal cortex and 
reduced amount of these receptors in the hippocampus. In the present study, a 
similar tendency was established in the frontal cortex. The “anxious” animals 
had more CCK binding sites compared to the “non-anxious” counterparts, but 
this difference was not statistically significant. In the hippocampus the situa­
tion was completely different. Namely, we found an increased number of 
[3H]pCCK-8 binding sites in the “anxious” animals compared to home-cage 
controls. Some support for the involvement of hippocampal CCK in the 
anxiogenic-like behaviour has been published. The recent studies indicate that 
CCK receptors in the hippocampus belong to the CCKB (brain) receptor 
subtype (Honda et al., 1993). Therefore, it is likely that the variations of 
exploratory behaviour in rats may be related to some extent to the differences in 
the density of CCKB receptors. There is evidence that unavoidable electric foot- 
shocks increase the levels of CCK-like immunoreactivity in limbic regions 
(Siegel et al., 1995). Moreover, the cessation of chronic 14-day diazepam 
treatment increased the number of CCK receptors in the hippocampus (Harro et 
al., 1990). The elevated levels of preproCCK mRNA in the hippocampus has 
been found after withdrawal from the 3-week diazepam treatment (Rattray et 
al., 1993). However, Pratt and Brett (1995) did not detect any changes in the 
content of preproCCK mRNA in the frontal cortex and hippocampus after the 
plus-maze exposure. Nevertheless, the administration of inverse benzodiazepine 
agonist FG 7142 at anxiogenic doses markedly increased the levels of 
preproCCK mRNA in both brain regions (Pratt and Brett, 1995). Despite the 
significantly distinctive behaviour, the plus-maze exposure may not be strong 
enough to increase CCK binding sites in the brain of all rats. Therefore, only in 
the most susceptible animals exposure to the elevated plus-maze caused the 
marked elevation of CCK binding sites in the hippocampus.
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The “anxious” rats displayed the reduced affinity of 5-HT2a receptors in the 
frontal cortex compared to home-cage controls and “non-anxious” rats. This 
change can be explained in the light of recent findings. Namely, Rex et al. 
(1993; 1994) and Marsden et al. (1993) established that the exposure of rodents 
to the elevated plus-maze increased the release of 5-HT in the frontal cortex. 
Similar alterations have also been described in the hippocampus (File et al., 
1993; Crawley and Corwin, 1994). Therefore, we are trying to speculate that 
the reduced affinity of 5-HT2a receptors in the frontal cortex is related to the 
increased release of 5-HT in the “anxious” rats. Moreover, two recent 
neurochemical studies have revealed a link between CCK and 5-HT in the 
regulation of exploratory behaviour. More specifically, the anxiogenic-like 
action of CCK agonists in the plus-maze is related to the increased release of 
5-HT in the prefrontal cortex (Rex et a l, 1997; Rex and Fink, 1998).
Besides CCK and 5-HT, also dopamine is shown to be involved in the 
regulation of anxiety (Glavin, 1993; Ladurelle et al., 1995). However, we did 
not find any significant modifications of dopamine D2 receptors in the striatum 
of selected rats. Accordingly, we were unable to establish a link between 
striatal dopamine receptors and exploratory behaviour.
We investigated also the release of anterior pituitary hormones in relation to 
the exploratory behaviour of rats. In the present study neither the exposure of 
rats to the plus-maze nor distinctive exploratory activity correlated with the 
serum levels of anterior pituitary hormones prolactin and thyrotropin. This is in 
line with results from the human studies where no difference between panic 
patients and healthy volunteers in the serum levels of thyrotropin-releasing 
hormone was found (Fossey et al., 1993). Only the concentrations of the 
growth hormone (GH) were significantly different in the selected rats. Namely, 
the “non-anxious” rats had markedly lower levels of GH compared to the 
“anxious” and intermediate groups. Anterior pituitary hormones are regulated 
by a multitude of classic neurotransmitters such as 5-HT and dopamine but also 
by neuropeptide transmitters (Tuomisto and Männistö, 1985). It has been 
shown that 5-HT stimulates the baseline release of GH and may be involved in 
the stress-induced GH elevation in man (Chamey et al., 1987). CCK also 
participates in the regulation of GH. The activation of CCKA receptors inhibits 
GH secretion while the activation of CCKB receptors caused the opposite effect 
(Männistö et al., 1994; Peuranen et al., 1994). Therefore, the increased levels 
of GH in the “anxious” animals might be caused by the increased activity of 
5-HT and CCK in the brain.
In conclusion, the present study confirms the significant individual 
differences in the exploratory behaviour of rats. Therefore, for performing of 
studies on animals involving exploratory behaviour, the animal groups should 
be big enough, consist of 10-12 animals at least to reduce the effect of 
individual variability. We were able to confirm the relation of individual 
behavioural differences to the activity of CCK-ergic neural circuits However,
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the variations in hormonal levels and receptor parameters between the selected 
groups are not as marked as in the behavioural studies. Nevertheless, the 
increased density of CCK receptors in the hippocampus and reduced affinity of 
5-HT2a receptors in the frontal cortex seem to be linked to the decreased 
exploratory activity of rats in the elevated plus-maze. The background of 
changes in the content of GH remains to be elucidated, but it may be also 
related to the altered activity of 5-HT and CCK neurotransmission in the brain.
5.3. Interaction between CCK and endopioid mechanisms 
in anxiety (papers П, IV)
The opioid agonist morphine (1.0 mg/kg) significantly increased the explora­
tory behaviour of rats in the plus-maze (Figure 5). The locomotor activity in the 
motility boxes remained unchanged at 1.0 mg/kg of morphine. Lower 
(0.5 mg/kg) and higher doses of morphine (2.5 mg/kg) were without any 
significant effect in the plus-maze, whereas a higher dose tended to reduce the 
locomotor activity of animals in the motility boxes. That could be a reason for 
the lack of anxiolytic-like activity of a higher dose of morphine as the reduced 
motor activity masks the changes in exploratory behaviour. Reduced locomotor 
activity accompanying the administration of a higher dose (2.5 mg/kg) of 
morphine is possibly due to the inhibition of dopaminergic neurotransmission 
in the mesolimbic structures (Lang et al., 1995). Opioid antagonist naloxone 
(0.5 mg/kg and 10 mg/kg) itself was unable to modify exploratory behaviour. 
Nevertheless, 10 mg/kg of naloxone tended to reduce the activity of rats in the 
plus-maze (Figure 5). The administration of non-selective CCK agonist 
caerulein (1 and 5 jLig/kg) and a selective CCKB receptor agonist BOC-CCK-4 
(1, 10 and 50 |Hg/kg) dose-dependently reduced the exploratory activity of rats 
in the elevated plus-maze (Figure 5). One |Ug/kg of caerulein was unable to 
decrease the exploratory behaviour, whereas 5 |ig/kg induced a significant 
reduction in all the studied parameters. Also, treatment with BOC-CCK-4 
(10 and 50 fig/kg) caused the anxiogenic-like behaviour of rats. The CCKB 
receptor antagonist L-365,260 (10 Hg/kg) displayed anxiolytic-like behaviour 
increasing the ratio between open and total arm entries (Figure 5).
Naloxone (0.5 mg/kg) potently antagonised the anxiolytic-like effect of 
morphine. CCKB receptor agonist BOC-CCK-4 (10 (ig/kg), also blocked the 
action of morphine (Figure 6). The combination of naloxone (0.5 mg/kg) with 
the sub-effective doses of caerulein (1 Mg/kg) and BOC-CCK-4 (1 |ng/kg) 
induced a robust decrease in the exploratory behaviour of rats (Figure 7). The 
combination of L-365,260 (100 |Jg/kg) with the sub-effective dose of morphine 
(0.5 mg/kg) caused the anxiolytic-like action in the plus-maze not seen if the 
drugs were given alone (Figure 8).
33
Dose, fjg/kg
Figure 5. The effects of caerulein, BOC-CCK-4, morphine, L-365,260 and naloxone 
upon the elevated behaviour of rats in the plus-maze. * — p<0.05, compared to vehicle- 
treated rats.
In the single-treatment experiments we established clear antagonistic influence 
of CCK agonists and opioid agonist on the exploratory behaviour of rats. Thus, 
CCK agonists have anxiogenic-like, while morphine has anxiolytic-like effect. 
It has been shown that microinjections of morphine into the central nucleus of 
amygdala counteracted the reduction in social interaction caused by an 
unfamiliar test arena but not by the increased lighting conditions (File and 
Rodgers, 1979). Moreover, it has been suggested that opioid peptides may be 
released under non-painful stress (exposure to the open-field test) (Rodgers and 
Deacon, 1979). BOC-CCK-4 antagonised the anxiolytic-like effect of 
morphine, but CCK agonist possessed U-shaped action against morphine in the 
plus-maze (Figure 6). Namely, 10 i-ig/kg of BOC-CCK-4 reversed the 
anxiolytic-like effect of morphine, whereas the other doses of CCK agonists 
were ineffective. Antagonistic interaction between CCK and endogenous 
opioids has described in the regulation of pain processing (Dourish et al., 
1988). In our opinion such interplay is valuable also in the regulation of 
exploratory behaviour.
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In addition to the anxiogenic-like effect of CCK-agonists we found the 
anxiogenic-like action enhancing effect of naloxone (Figure 5). BOC-CCK-4 
and caerulein induce the anxiogenic-like action via the CCKB receptors as we 
have shown above. The coadministration of naloxone (0.5 mg/kg) with the sub­
effective doses of caerulein and BOC-CCK-4 induced a potent anxiogenic-like 
action in the elevated plus-maze (Figure 7). This finding is apparently in favour 
of an antagonistic interplay between CCK and endogenous opioid peptides in 
the regulation of anxiety and the importance of ц-opioid receptors in that. 
Neurochemically, a biphasic effect of morphine upon the release of CCK-LI 
has been described. Lower doses of morphine decreased the release of CCK, 
and this effect was preventable with ji-antagonist naloxone, whereas 100 times 
higher doses increased the release of CCK-LI by stimulating 8-opioid receptors 
(Benoliel et al., 1994).
As morphine is an agonist for fi-opioid receptors and a low dose of naloxone 
is able to reverse the action of morphine, it is very likely that ц-receptors 
participate in the regulation of exploratory behaviour. Indeed, Motta and 
Brandao (1993) have shown that the systemic administration of morphine at 
low doses or its injection into the dorsal periaqueductal grey induced 
anxiolytic-like action in the elevated plus-maze. Microdialysis studies on freely 
moving rats confirmed the inhibition of CCK release in the frontal cortex by the 
stimulation of |Li-opioid receptors (Benoliel et al., 1998). Some studies have 
found the ability of CCK to antagonise the effects of morphine on cellular 
levels and influence the properties of fi-opioid receptors (Wang et al., 1992; 
Liu et al., 1995). In relation to our study, these findings confirmed the |i-opioid 
receptors as site for the described interaction.
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Figure 6. The effect of naloxone (0.5 mg/kg) and BOC-CCK-4 (1-50 (ig/kg) on the 
anxiolytic-like action of morphine (1 mg/kg) in the elevated plus-maze. S —  saline, 
M — morphine, N —  naloxone, B1 —  BOC-CCK-4 1 Ц-g/kg, B10 — BOC-CCK-4 
10 |ig/kg and B50 — BOC-CCK-4 50 M-g/kg. * —  p<0.05 compared to saline-treated 
animals; + —  p<0.05 compared to morphine-treated animals.
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Figure 7. The action of sub-effective doses of caerulein (1 (Jg/kg) and BOC-CCK-4 
(1 Mg/kg) alone and in combination with naloxone (0.5 mg/kg) in the elevated plus- 
maze. Sal —  saline, Nal — naloxone, Caer —  caerulein, C4 — BOC-CCK-4.
* — p<0.05 compared to saline-treated animals; + — p<0.05 compared to BOC-CCK-4- 
treated animals.
CCKB receptor antagonist L-365,260 alone expressed the anxiolytic-like 
activity only at one dose (10 |ig/kg), having the characteristic bell-shaped dose- 
response curve described by several authors earlier (Hughes et al., 1990; 
Ravard et al., 1990; Harro and Vasar, 1991). Also, the combination of 
L-365,260 with the sub-effective dose of morphine (0.5 mg/kg) induced an 
anxiolytic-like action. Again L-365,260 was effective only at one dose 
100 |ag/kg (Figure 8). It is worthy to note that this dose of L-365,260 did not 
change the exploratory activity of rats per se showing that the interaction 
between L-365,260 and morphine was specific. The potentiation of the action 
of morphine by the CCKB receptor antagonist could also be explained in the 
light of the recent finding that stimulation of |i-receptors decreases the release 
of CCK in the frontal cortex of rat (Benoliel et al., 1998). Moreover, this dose 
of L-365,260 (100 ng/kg), but not the lower doses, antagonised the anxiogenic- 
like action of caerulein, an agonist of CCK receptors (Figure 2) (Vasar et al., 
1997). Altogether these data are in favour of the antagonistic interaction 
between morphine and CCK in the regulation of exploratory behaviour.
Several studies indicate the antagonistic interaction between CCK and en- 
dopioid peptides in the regulation of pain sensitivity. However, as in the present 
work, the action of CCK was dependent on the pre-experimental stress of rats. 
Wiertelak et al. (1992) have shown that CCK antagonises morphine-induced 
antinociception only in the novel but not in the familiar environment. This 
finding was confirmed by Lavigne et al. (1992) demonstrating that CCK 
antagonists devazepide and L-365,260 enhanced morphine-induced analgesia
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Figure 8,. Interaction of L-365,260 (10-1000 Ц-g/kg) with the sub-effective dose 
(0.5 mg/kg) of morphine. V — vehicle, S — saline, M — morphine, L10 —  L-365,260 
10 (ig/kg, L100 — L-365,260 100 pg/kg, L1000 —  L-365,260 1000 fig/kg. 
* — p<0.05 compared to saline-treated animals; + —  p<0.05 compared to morphine- 
treated animals.
only in non-acclimatised rats exposed to the novel environment. Therefore, it is 
likely that even in the case of pain regulation the interplay between CCK and 
endogenous opioid peptides may be actually dependent on the level of anxiety. 
This suggestion is supported by the recent study of Benedetti et al. (1997) who 
found that nocebo-induced hyperalgesia was reversed dose-dependently by 
CCK antagonist proglumide but not by naloxone. Since the nocebo procedure 
represents an anxiogenic stimulus, it is likely that nocebo hyperalgesia may be 
due to a CCK-dependent increase of anxiety.
In conclusion, CCK and endopioid mechanisms have an opposite role in the 
behavioural response of animals towards the novel environment. The 
simultaneous stimulation of CCKb receptors and the blockade of |l-opioid 
receptors apparently increase anxiety in rats. On the other hand, morphine, an 
agonist for jn-opioid receptors, potently increased the exploratory behaviour of 
rats in the elevated plus-maze, and that effect was completely antagonised by 
stimulation of CCKb receptors with BOC-CCK-4. Moreover, the combination 
of the sub-effective dose of morphine with CCKb receptor antagonist 
L-365,260 potentiated the anxiolytic-like action of ц-receptor agonist. 
According to these series of experiments, the antagonistic interplay between 
CCKB and ц-opioid receptors in the regulation of exploratory behaviour is 
evident.
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5.4. Serotonin release induces anti-exploratory action and 
increases the activity of CCK-ergic transmission (paper III)
The administration of SSRI paroxetine (0.5, 2, 4, 8 mg/kg) induced a dose- 
dependent reduction of exploratory activity of rats in the motility test (Fig­
ure 9). Also, the same doses of paroxetine (4 and 8 mg/kg) elevated the density 
of CCK binding sites in the frontal cortex but not in the hippocampus (Fig­
ure 10). Paroxetine itself was unable to modify the binding of CCK (data not 
shown). In the elevated plus-maze only 8 mg/kg of paroxetine had a clear 
anxiogenic-like action. Moreover, CCKB antagonist LY 288,513 dose- 
dependently reversed the anti-exploratory activity of 2 mg/kg paroxetine 
(Figure 11) but not the effect of higher dose of paroxetine (8 mg/kg). Diazepam 
at a high dose (2.5 mg/kg) suppressed the exploratory behaviour of rats in the 
motility test. The combination of diazepam (0.5, 1, 2.5 mg/kg) with paroxetine 
(2 mg/kg) did not modify the anxiogenic-like effect of SSRI.
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Figure 9. The effect of paroxetine (0.5-8 mg/kg), diazepam (0.5-2.5 mg/kg), and 
LY288, 513 (0.01-1 mg/kg) on the exploratory behaviour of rats in the motility box.
* — p<0.05 compared to saline (paroxetine) or vehicle-treated (diazepam, LY288,513) 
rats.
The administration of paroxetine, a selective inhibitor of 5-HT reuptake, 
induced a significant suppression of the exploratory activity of rats in the 
motility test. Already 2 mg/kg of paroxetine inhibited the frequency of rearing 
and time spent in rearing. The frequency of rearing and time spent in rearing 
are the most sensitive parameters in revealing the anti-exploratory action of 
paroxetine in the motility test. Moreover, paroxetine was apparently less potent 
in reducing the exploratory activity of rats in the elevated plus-maze. Only
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8 mg/kg of paroxetine decreased the exploratory behaviour of animals. The 
decreased number of closed arm entries reflecting the suppression of locomotor 
activity accompanied the anti-exploratory action of paroxetine in the plus-maze. 
Therefore, it is very likely that the decreased locomotor activity may mask the 
“pure” anti-exploratory effect of paroxetine in the elevated plus-maze. Similar 
results are described in a recent paper, where only 0.0027 |imol/kg (1 mg/kg) of 
paroxetine decreased exploratory behaviour and higher doses tended to sup­
press the locomotor activity of animals (Sanchez and Meier, 1997). The 
existing experimental data support the role of 5-HT in the regulation of anxiety. 
Handley and McBlane (1993) have shown that the administration of fluoxetine, 
the 5-HT reuptake inhibitor, induces the anxiogenic-like action in the rat 
elevated plus-maze. The administration of paroxetine produced an anxiogenic- 
like profile in the two-compartment exploration test of rat (Sanchez and Meier, 
1997). The exposure of rats to the aversive environment clearly increases the 
release of 5-HT in the frontal cortex and hippocampus (File et al., 1993; Rex et 
al., 1994). However, as diazepam was not able to reverse the effect of 
paroxetine, the present behavioural study suggests that the anti-exploratory 
action of paroxetine is related rather to the decrease of exploratory drive than to 
the increase in anxiety.
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Figure 10. The effect of paroxetine (0.5-16 mg/kg) on the parameters of CCK binding 
in the frontal cortex and hippocampus. * — p<0.05 compared to saline-treated rats.
Rosen et al. (1995) have shown that 5-HT reuptake inhibitor alaproclate 
increases the levels of CCK in the cingulate cortex and periaqueductal grey. 
The direct application of 5-HT to the neurones of the cerebral cortex and 
nucleus accumbens evoked the release of CCK (Raiteri et al., 1993). In the pre­
sent study paroxetine, the compound with the highest 5-HT uptake inhibitory 
potency in vivo, elevated the number of CCK binding sites in the frontal
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Figure 11. The effect of LY288.513 (0.01-1 mg/kg) on the anti-exploratory action of 
paroxetine (2 mg/kg). CONT —  saline + vehicle, PRX2 —  paroxetine 2 mg/kg + 
vehicle, LY0.01 —  LY288,513 0.01 mg/kg, LY0.1 —  LY288,513 0.1 mg/kg, 
LY1.0 —  LY288,513 1.0 mg/kg. * —  p<0.05 compared to saline + vehicle-treated rats, 
+ —  p<0.05 compared to paroxetine-treated rats.
cortex but not in the hippocampus. The stressful manipulations in rats are 
shown to increase the density of CCK receptors and mRNA levels of 
preproCCK in the frontal cortex (Pratt and Brett, 1995; Harro et al., 1995a). 
The social isolation of rats for seven days induced an anxiogenic-like action 
and elevated the number of CCK receptors in the frontal cortex but not in the 
hippocampus (Vasar et al., 1993). Therefore, it is not surprising that the pre­
treatment of rats with the CCKB receptor antagonist LY 288,513 dose- 
dependently reversed the anti-exploratory action of paroxetine (2 mg/kg). This 
is in line with the study of Matto et al. (1996) showing the ability of the 
CCKB receptor antagonist L-365,260 to antagonise the anti-exploratory effect 
of the 5-HT reuptake inhibitor citalopram in the elevated plus-maze. These data 
are in favour of the hypothesis that the administration of 5-HT reuptake 
inhibitors increases CCK-mediated neurotransmission in the brain. The 
antagonism of LY 288,513 against paroxetine seems to be specific since the 
CCKB receptor antagonist does not increase the exploratory activity per se. 
Moreover, it has been shown that SSRIs are able to antagonise the anxiolytic­
like effect of CCKB antagonist, CI-988 (Bickerdike et al., 1994). Therefore, 
synergistic interaction between 5-HT and CCK in the regulation of exploratory 
behaviour is evident. Nevertheless, LY 288,513 did not block the effect of the 
higher dose of paroxetine (8 mg/kg) showing a difference in the action of two 
doses of 5-HT reuptake inhibitor. This discrepancy could explain that paroxet-
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ine at higher doses induces a more pronounced increase in the concentration of 
5-HT in the synaptic cleft masking a possible interaction with CCK. Unlike the 
present study, Harro et al. (1997) did not find any changes in the density of 
CCK receptors and in the content of CCK-related peptides after a long-term 
treatment with various antidepressant drugs, including 5-HT reuptake inhibi­
tors. However, they analysed the action of long-term administration of 
antidepressant drugs, whereas the effect of acute treatment was not examined.
In conclusion, the selective 5-HT reuptake inhibitor paroxetine induced an 
anti-exploratory effect in the motility boxes. However, the above-described 
behavioural studies do not reflect the increase in anxiety after the acute 
treatment with paroxetine. This statement is supported by the findings that 
paroxetine did not cause the anxiogenic-like action in the elevated plus-maze 
and diazepam, a potent anxiolytic drug, did not antagonise the anti-exploratory 
action of paroxetine in the motility test. Therefore, it is likely that paroxetine 
may reduce the exploratory drive in rats and makes animals more susceptible to 
the novel environment. This effect of paroxetine seems to be mediated via the 
increase in CCK-ergic neurotransmission.
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6. GENERAL DISCUSSION
The present study provides further evidence that the exploratory behaviour of 
rats is influenced by the different environmental stimuli. Moreover, we 
confirmed the synergistic interaction between CCK and 5-HT and the 
antagonistic interplay between CCK-endopioid mechanisms in the regulation of 
anxiety. It has been shown that CCK-ergic neurotransmission is activated in the 
cortical and hippocampal areas during anxiogenic events (Rattray et al., 1993). 
Moreover, an increased release of 5-HT in the frontal cortex is a clear 
neurochemical change during the exposure to the aversive environment (Rex 
and Fink, 1998). The animals who are more susceptible to the aversive 
environmental stimuli and who respond with anxiogenic-like behaviour to 
novel situations have activated CCK- ergic and 5-HT-ergic neural circuits. This 
feature seems to decrease their ability for adaptation to environmental changes. 
Interestingly, in panic patients several biochemical changes reflecting the 
alterations in the CCK neurotransmission have been described (Koszycki, 
1995). Additionally, patients with panic attacks have been shown to be more 
sensitive to panicogenic CCK-4 (Bradwejn et al., 1991). Moreover, in humans 
the vulnerability to unpleasant situations or anxiety sensitivity has been 
described as a prominent characteristic of panic patients (Koszycki et al., 
1993). On the other hand, no straightforward correlation between anxiety 
sensitivity scale and response to the CCK-4 has been established as yet 
(Koszycki et al., 1996). However, results from studies with animals are 
supportive to the hypothesis that vulnerability to the anxiety disorders is a 
consequence of the activation of CCK neurotransmission.
According to the hypothesis of Wiertelak et al. (1992), the environmental 
stimuli that signal the occurrence of aversive or dangerous events activate 
endogenous opioid analgesia systems. The signals for safety (the non-occur­
rence of aversive events) produce the opposite and inhibit environmentally 
produced analgesia. Wiertelak et al. (1992) believe that CCK is a mediator of 
that kind of safety signals. However, the present study is not in favour of that 
statement since CCK apparently increases anxiety in the novel environment and 
the anxiogenic-like action of CCK was potentiated by opioid antagonist 
naloxone. Moreover, CCK agonist reversed the anxiolytic-like activity of 
morphine. Therefore, CCK-ergic pathways would rather signal the unsafe and 
aversive aspects of environment.
Seasonal fluctuations in the activity of 5-HT circuits are well known and 
have been described by several authors (Nagayama and Lu, 1998). Such 
variation is believed to be the reason for the seasonality of affective disorders 
(Maes et al., 1993). This kind of seasonality exists also in the patients suffering 
from the panic disorder, but the biochemical correlates causally linked to the
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circannual variations are not known as yet. We were able to confirm the annual 
rhythm in the responsiveness to the aversive environment in the animals kept 
under constant temperature and the light-dark period. Accordingly, decreased 
exploratory behaviour of animals in summer correlates with increased activity 
in the CCK-ergic and 5-HT- ergic neurotransmission in the cortical regions. 
This finding strongly suggests that circannual rhythm is endogenous based on 
the changes in the “internal clock”. As concentration of ACTH has been 
described to follow a similar fluctuation (Amirat and Brudieux, 1993), we are 
tempting to speculate the connection between CCK and HPA axis in the 
circannual variations. In our opinion, the natural pressure activates neural 
“fear” circuits, which is an important adaptive event in wildlife where fear is a 
life-saving response to the threatening dangers. Therefore, in summer labora­
tory animals become more susceptible to the unpleasant environmental stimuli, 
and their exploratory activity or “curiosity” decreases. This kind of defence 
reaction is highly conserved in evolution and is indispensable for survival in the 
continuously changing world. Over-reactivity in that system leads to various 
psychopathological diseases, named anxiety disorders.
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7. CONCLUSIONS
1. Pre-experimental stress and isolation of animals after injection makes them 
sensitive to the anxiogenic-like effect of caerulein, an agonist of CCK 
receptors. Decreased exploratory behaviour of rats in summer is related to 
the increased CCK-ergic and 5-HT-ergic activity in the brain areas that are 
most involved in the generation of response to the unpleasant stimulus.
2. Differences in the exploratory behaviour are probably caused by the 
individual differences in the CCK-ergic and 5-HT-ergic neurotransmissions. 
Increased activity in the CCK-ergic neural circuits in the hippocampus 
seems to make animals more susceptible to the exposure to the unpleasant 
environment. This finding supports the opinion that the “endogenous tone” 
in the interaction of CCK-ergic and 5-HT-ergic neural circuits modifies the 
“basal” exploratory activity of animals. Animals having higher “endogenous 
tone” in those circuits express marked avoidance behaviour in the elevated 
plus-maze.
3. Taken together, in planning of the ethological experiments to study the 
exploratory behaviour, the design and conditions of test should be cautiously 
analysed to reduce the variability of the results. Most probably, according to 
our present work, inconsistencies in the studies with the CCK-ergic 
compounds are caused by significant seasonal and individual fluctuations in 
the exploratory behaviour.
4. CCK and endopioid mechanisms have an opposite influence in the regula­
tion of exploratory behaviour. Activation of CCKB receptors decreases, 
whereas the stimulation of (j.-opioid receptors increases the exploratory 
behaviour of animals. Most likely, activation of endogenous opioid mecha­
nisms signals that the surrounding environment is safe and not life- 
threatening.
5. Interaction between 5-HT and CCK is synergistic in the generation of 
anxiogenic-like behaviour. Activation of 5-HT neurotransmission decreases 
the exploratory drive and increases CCK-ergic transmission. An increased 
release of 5-HT induced by paroxetine forces animals to avoid the 
unfamiliar and potentially dangerous environment. Thus, CCK and 5-HT are 
signals that environment is unsafe and dangerous and should be avoided.
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SUMMARY IN ESTONIAN
KOLETSÜSTOKINIINIST PÕHJUSTATUD 
ÄREVUS — KESKKONNASTIIMULITE MÕJU NING 
SEOSED ENDOPIOIDSETE MEHHANISMIDEGA JA 
SEROTONIINIGA
Koletsüstokiniin (CCK) on peptiid, mis avastati esmakordselt seedetraktis. 
Järgnevad uuringud näitasid, et tegemist on ainega, mida esineb laialdaselt ka 
ajus. Tänapäeva seisukohtade järgi ongi CCK ajus enim levinud peptiidse 
struktuuriga neuromediaator. Kesknärvisüsteemis (KNS) leiduv CCK on seotud 
toitumiskäitumise kujunemisega, valuaistingu modulatsiooniga, motivatsiooni­
de ja emotsioonide regulatsiooniga. Bioloogilises psühhiaatrias on CCK pälvi­
nud tähelepanu kui virgatsaine, mis osaleb ärevus- ja paanikahäirete patoge- 
neesis. CCK-4 manustamine kutsub esile paanikahooge nii katseloomadel kui 
ka inimestel. Täheldatud on CCKB alatüübi retseptorite antagonistide anksio- 
lüütilist toimet. Vaatamata esialgsetele paljulubavatele katsetulemustele, on 
edasised uuringud olnud üsna vasturääkivad ning tulemuste varieeruvus eri 
katsetes suur. Kirjanduse andmed viitavad ka teiste neuromediaatorite, ees­
kätt serotoniini (5-HT) ja endopioidide rollile CCK poolt indutseeritud ärevuse 
tekkes.
Uurimuse eesmärgid
1. Uurida katse-eelse stressi mõju CCK agonisti tseruleiini anksiogeensele toi­
mele ning selgitada eksploratiivse aktiivsuse sesoonsete erinevuste taga­
maid.
2. Selgitada neurokeemilisi protsesse, mis tingivad katseloomade uudistamis- 
aktiivsuse varieeruvuse tõstetud plusspuuris.
3. Uurida ja selgitada CCK ning endopioidsete mehhanismide vahelist interakt­
siooni eksploratiivse käitumise regulatsioonis.
4. Selgitada 5-HT ja CCK vahelist interaktsiooni ärevuskäitumise tekkes.
Uurimismeetodid
Käitumiskatsetes kasutati isaseid Wistari liini rotte (Han/Kuo: WIST). Käitu -
miskatseseadmeteks olid tõstetud plusspuur ja  automatiseeritud motoorika jäl­
gimise süsteem. Osale loomadele rakendati katse-eelse manipulatsioonina kas
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loomade “käsitsemist” (ingl. k. handling) või lühiajalist isolatsiooni pärast 
tseruleiini manustamist. Leidmaks eksploratiivse aktiivsuse individuaalsete eri­
nevuste neurokeemilisi põhjuseid, jagati rotid vastavalt uudistamisaktiivsusele 
gruppidesse. Käitumiskatsetega paralleelsetelt tehti ka neurokeemilisi uurin­
guid, milles hinnati aju retseptoorsete süsteemide seisundit ja adenohüpofü- 
saarsete hormoonide sisaldust veres. Selgitamaks mediaatorsüsteemidevahelisi 
interaktsioone, kasutati vastavatesse süsteemidesse toimivaid agoniste või anta­
goniste.
Tulemused
Uuringud katse-eelsete stressoritega näitasid, et tseruleiini anksiogeenne toime 
sõltub katseloomadega tehtavatest katse-eelsetest manipulatsioonidest. Nimelt 
avaldas tseruleiin (5 jLtg/kg) kõige tugevamat anksiogeenset toimet neisse rotti­
desse, keda eelnevalt ei “käsitsetud” ega asetatud pärast süsti üksikult rida- 
puuri. Loomadele, keda oli “käsitsetud” ja kes asetati pärast süsti tagasi kodu- 
puuri, ei avaldanud tseruleiin mingit toimet.
Uuringu teises osas võrreldi katseloomade uudistamisaktiivsust kahel aasta­
ajal — suvel (juuni) ja talvel (november). Leiti katseloomade väga suur 
uudistamisaktiivsuse sesoonne erinevus. Rottide eksploratiivne aktiivsus oli 
suvel oluliselt väiksem kui talvel. Peale selle oli suvel rottidel oluliselt rohkem 
CCK-retseptoreid ajukoores ja hipokampuses ning 5-HT2A-retseptoreid aju­
koores. Samuti oli kasvuhormooni kontsentratsioon seerumis suvistel rottidel 
suurem kui talvistel.
Järgnevates uuringutes leiti, et katseloomade uudistamisaktiivsus erines 
indiviiditi väga oluliselt. Selline jaotumine võimaldas jagada rotid kolme grup­
pi: ärevad, vahepealsed ja mitteärevad. Mitteärevad rotid viibisid pluss-puuri 
avatud õlgadel keskmiselt 38±8 sekundit (s.o 13% katseajast), samas kui ärevad 
ei väljunud üldse avatud õlgadele. Radioligandsidumiskatsetega leiti, et vähese 
uudistamisaktiivsusega (ärevatel) rottidel oli hipokampuses CCK- retseptorite 
arv suurenenud, ajukoores aga 5-HT2A-retseptorite afiinsus vähenenud. Adeno- 
hüpofüüsi hormoonidest ilmnesid muutused ainult kasvuhormooni sisalduses, 
mitteärevatel ja plusspuuril mittekäinud rottidel oli võrreldes ärevate loomade­
ga veres oluliselt vähem kasvuhormooni.
CCK ja endopioidide vahelist interaktsiooni uurides sedastati, et morfiinil
oli selge anksiolüütiline toime (1,0 mg/kg), naloksoon ei mõjutanud aga 
uudistamiskäitumist üldse. CCK agonistid tseruleiin ja BOC-CCK-4 avalda­
sid doosist sõltuvat anksiogeenset toimet. CC Кв-retseptorite antagonistil 
L-365,360-1 oli anksiolüütiline toime, kuid annuse toime kõver oli iseloomuliku 
tagurpidise U kujuga, ainsaks efektiivseks doosiks oli 10 |Xg/kg. Kombineerides 
alaläviseid tseruleiini või BOC-CCK-4 annuseid naloksooni väikese annusega 
(0,5 mg/kg), saadi tugev anksiogeenne toime. Selgus ka, et morfiini anksio-
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lüütiline toime oli kõrvaldatav naloksooni 0,5 mg/kg annusega ja 10 |ig/kg 
BOC-CCK-4-ga. Teisalt, morfiini alalävise annuse (0,5 mg/kg) kombinatsioon 
L-365,360-ga doosis 100 (xg/kg andis anksiolüütilise toime.
Paroksetiin on tugevaima toimega selektiivne serotoniini tagasihaarde in­
hibitor (SSRI) nii in vitro kui ka in vivo. Paroksetiin langetas doosist sõltuvalt 
katseloomade uudistamisaktiivsust, efektiivsete doosidega 2, 4 ja  8 mg/kg. 
Doosid 4 ja 8 mg/kg suurendasid ka CCKB-retseptorite arvu roti ajukoores, kuid 
mitte hipokampuses. Diasepaam ei suutnud kõrvaldada paroksetiini anksiogeen- 
set toimet, kui CCKB antagonist LY 288,513 annuses 1,0 mg/kg kõrvaldas täie­
likult paroksetiini toime annuses 2 mg/kg. Suuremate paroksetiini annuste anti- 
eksploratiivset toimet CCKB antagonist ei kõrvaldanud.
Järeldused
1. CCK-ergiliste ainete toime on tugevam pärast katse-eelseid stressoor- 
seid (ilma “käsitsemiseta” ja  isolatsioon) manipulatsioone. Seega sõltub 
CCK-ergiliste ainete toime endogeensest CCK-neuronite toonusest. Katse­
loomade uudistamiskäitumise vähenemine suvekuudel on seotud CCK- ja 
5-HT-ergiliste närviringide aktivatsiooniga.
2. Loomade eksploratiivne aktiivsus sõltub CCK- ja 5-HT-ergiliste närviringi­
de aktivatsioonist. Suurenenud aktiivsus nimetatud ringides viib organismi 
kohanemisvõime vähenemisele, mis katseloomadel avaldub uudistamis- 
aktiivsuse vähenemises.
3. Loomade eksploratiivse käitumise kirjeldatud individuaalsed ja sesoonsed 
erinevused on kindlasti üheks eri uurimisgruppide ebapüsivate tulemuste 
põhjuseks. Seetõttu tuleb käitumiskatsete planeerimisel arvestada kirjelda­
tud variatsioonidega ja võimalusel katsetingimusi ühtlustada.
4. CCK-1 ja endopioidsetel mehhanismidel on uudistamiskäitumise regulat­
sioonis teineteise suhtes antagonistlik mõju. CCKB-retseptorite aktivatsioon 
vähendab, samas kui ja-opioidiretseptorite aktivatsioon suurendab katse­
loomadel uudistamisaktiivsust.
5. CCK ja 5-HT vaheline interaktsioon anksiogeense käitumise kujunemisel on 
sünergistlik. 5-HT neurotransmissiooni aktivatsioon vähendab uudistamis­
aktiivsust ja see toime korreleerub CCK-ergiliste neuronite aktivatsiooniga. 
5-HT suurem vabanemine põhjustab katseloomadel uudset situatsiooni 
vältiva käitumise.
Kokkuvõtvalt võib öelda, et katseloomade uudistamiskäitumise kujunemises 
osalevad närviringid on olulised ka loomade reaktsioonis ebameeldivale ja 
uudsele keskkonnale. CCK- ja 5-HT-ergiliste ringide aktivatsioon halvendab 
adaptatsiooni uudse situatsiooniga ning tingib sellest hoidumise. Endopioidsete 
mehhanismide aktivatsioon teisalt aga parandab isendi kohanemist uudse kesk­
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konnaga. CCK poolt kontrollitava vältiva käitumise näol on tegemist evolut­
siooniliselt vana ja  konserveerunud käitumisega, mis tagab isendi püsima­
jäämise muutuvas maailmas. Et kirjeldatud skeem on tähtis lüli ärevushäirete 
patogeneesis, on oluline nende närviringide põhjalikum tundmaõppimine ja  
defineerimine.
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Abstract
Forty-five male Wistar rats were selected according to their behavior in the elevated plus-maze. They were separated as follows: 
animals with low exploratory activity ( ‘anxious’), an ‘intermediate’ group and animals having high exploratory activity ( ‘non-anxious’). 
Various receptor binding studies and hormonal assays were also performed in these selected rats. The affinity of 5-hydroxytryptamine 
5-HT2a receptors in the frontal cortex was lower in the ‘anxious’ rats compared to home-cage controls and ‘non-anxious’ animals. 
Moreover, the number of cholecystokinin (CCK) receptors in the hippocampus was significantly elevated in the ‘anxious’ group compared 
to home-cage control animals. The blood levels of growth hormone (GH) were significantly lower in the ‘non-anxious’ rats compared to 
‘anxious’ counterparts. In conclusion, it seems likely that the decreased exploratory activity of rats is related to the increased 
5-hydroxytryptamine (5-HT) and CCK mediated neurotransmission in the brain. The different serum levels of GH in the selected rats 
probably reflect alterations in the activity of 5-HT and CCK. © 1997 Elsevier Science B.V.
Keywords: Elevated plus-maze; Exploratory activity; Selection of rats; Neurotransmitter receptors; Blood hormone levels
1. Introduction
Rägo et al. (1988, 1991) and Нагто et al. (1990) showed 
that it was possible to categorise rodents according to their 
exploratory behavior in the elevated plus-maze. The ex­
ploratory behavior of rodents having the lowest activity 
resembled to that of animals treated with the anxiogenic 
ß-carbolines (1DMCM, FG 7142), whereas the behavior of 
high activity animals was similar to the administration of 
diazepam. In addition, Rägo et al. (1988) have established 
the reduced number of benzodiazepine and GABAa re­
ceptors in the cerebral cortex of ‘anxious’ mice compared 
to their ‘non-anxious’ counterparts. Harro et al. (1990) also 
reported a reduced density of benzodiazepine receptors in 
the ‘anxious’ rats simultaneously with an increased number
’Corresponding author. Tel.; +372 7 465334; fax: +372 7 422044; 
e-mail: sulev.koks@ut.ee
of cholecystokinin (CCK) receptors in the frontal cortex. 
The administration of the benzodiazepine inverse agonist 
FG 7142 in anxiogenic doses (10-20 mg/kg) increased the 
density of CCK receptors in rat frontal cortex (Harro et al., 
1990). These findings support the antagonistic interaction 
between CCK and benzodiazepine/GABAA receptors first 
established in the electrophysiological study of Bradwejn 
and de Montigny (1984).
However, not only are CCK (Crawley and Corwin, 
1994; Harro et al., 1993) and benzodiazepine/GABAa 
(Handley, 1994) receptors are involved in the regulation of 
anxiety, but neuronal 5-hydroxytryptamine (5-HT) 
(Iversen, 1984; Andrews and File, 1993; Handley and 
McBlane, 1993, Marsden et al., 1993) and dopamine 
(Pratt, 1992; Glavin, 1993; Vaccarino, 1994; Ladurelle et 
al., 1995) also have a role in the control of negative 
emotions. The administration of 5-HT receptor agonist as 
mCPP has been shown to catise anxiety in rodents as well
0924-977X/97/S17.00 © 1997 Elsevier Science B.V. All rights reserved. 
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in man (Handley, 1994). On the other hand, the drugs 
blocking 5-HT2 receptors have been proven to have an 
anxiolytic action (Barrett and Vanover, 1993). CCK and 
5-HT seem to interact in the regulation of anxiety since the 
administration of CCK-4 potentiates the release of 5-HT 
induced by the exposure of rodents to the plus-maze (Rex 
et al., 1994). L-365,260, an antagonist of CCKB (brain 
subtype) receptors, potenüy reversed this action of CCK-4 
(Rex et al., 1994). There is also some evidence that 5-HT 
may be a mediator of the anxiogenic-like effect of CCK in 
the plus-maze test (Vasar et al., 1993). Dopamine is the 
other neurotransmitter closely interacting with CCK in the 
regulation of behavior (Ladurelle et al., 1993; Crawley and 
Corwin, 1994). Evidence from the study of Glavin (1993) 
suggests that dopamine is also involved in the modulation 
of anxiety in rodents.
On the other hand, CCK, 5-HT and dopamine have also 
been shown to regulate the blood levels of anterior 
pituitary hormones (thyrotropin, growth hormone, prolac­
tin) (Tuomisto and Männistö, 1985; Chamey et al., 1987; 
Peuranen et al., 1995). We may therefore propose that 
anxiogenic-like behavior is related to neurochemical 
changes in the brain and these changes can also influence 
serum anterior pituitary hormone content. This stimulated 
the study of the relationship between the exploratory 
behavior and levels of anterior pituitary hormones. Ac­
cordingly, the aim of present study was to confirm and 
extend the data of experiments performed by Rägo et al. 
(1988, 1991) and Harro et al. (1990), and to find out 
whether the exploratory behavior in the elevated plus-maze 
is correlated with some radioligand binding and hormonal 
parameters.
The male Wistar rats were selected according to their 
exploratory behavior in the elevated plus-maze. The above 
mentioned studies suggest the implication of four different 
neurotransmitter systems (CCK, GABA, dopamine and 
5-HT) in the regulation of anxiety (Glavin, 1993; Handley, 
1994). Therefore, the various brain structures of selected 
rats were used for radioligand binding studies to reveal the 
parameters of dopamine D2 (in the striatum), 5-hydroxy- 
tryptamine 5-HT2A (in the frontal cortex), benzodiazepine 
(in the frontal cortex) and CCK receptors (in the frontal 
cortex and hippocampus). The levels of anterior pituitary 
hormones in serum were also measured.
2. Experimental procedures
2.1. Animals
The experiments were performed on male Wistar rats 
(Han/Kuo; Finnish National Laboratory Animal Center, 
Kuopio, Finland) weighing 260-360 g. The rats were kept 
four to five per cage at 21±2°C in a silent, dark room 
illuminated artificially from 7 a.m. to 7 p.m. They had 
laboratory pellets and water ad libitum. The experiments
were performed 10 days after the arrival of rats to the 
animal house from the breeding company. For the selec­
tion procedure 80 handling-naive animals were used. All 
the behavioral experiments were done between 12:00 and 
17:00. The animals were killed by decapitation immedi­
ately after the plus-maze exposure. Their brain structures 
were used for radioligand binding studies and the blood 
samples were taken to perform the hormonal experiments. 
The rats randomly taken from the home-cage (altogether 
16 rats) were employed as the control animals for the 
hormonal and receptor binding studies.
2.2. Exploratory activity in an elevated plus-maze
The method suggested initially by Handley and Mithani
(1984) for measuring exploratory activity was employed to 
study rats, with modifications as given by Pellow et al.
(1985). The apparatus consisted of two opposite open arms 
(50x10 cm) without side walls and two enclosed arms 
(50X10X40 cm) with side walls and end wall, extending 
from a central square (10X 10 cm). The maze was elevated 
to the height of 50 cm, and placed in a lit room (110 
radiometric lux). During a 5 min observation session the 
following measures were taken by an observer: 1) number 
of attempts to enter from closed arm into the central 
square; 2) time spent in exploring central square and open 
arms of plus-maze; 3) number of closed and open arm 
entries. Subsequently, the ratio between open and closed 
arm entries was calculated. Af the beginning of the 
experiment an animal was placed at the center of the 
plus-maze, facing the closed arm. An arm entry was 
counted only when all four limbs of the rat were within a 
given arm.
2.3. Radioligand binding studies
After decapitation the brains were quickly dissected on 
ice. The binding studies were performed on the various 
brain structures of the rats. The striatum was used to 
determine the density and affinity of dopamine D2 re­
ceptors, the frontal cortex for 5-hydroxytryptamine 5- 
HT2A, benzodiazepine and CCK receptors, and the hip­
pocampus for CCK receptors (Table 1). These brain 
structures were selected according to results from previous 
studies since in these brain regions the most significant 
neurochemical changes had been established due to the 
elevated plus-maze exposure (Rägo et al., 1988, 1991; 
Harro et al., 1990; Rex et al., 1993; File et al., 1993). The 
brain tissue was homogenized in 20 volumes of ice-cold 50 
mM Tris-HCl (pH 7.4 at 4°C) using a Potter-S glass-teflon 
homogenizer (1000 rpm, 12 passes). The membranes were 
washed twice in the same buffer by centrifugation 
(48 000X# for 20 min) and resuspension. After the last 
centrifugation the crude brain membranes were suspended 
in the incubation buffer for the appropriate binding assay.
The protein content was measured according to a dye-
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Table 1
Basic data about the methods of receptor binding studies.
Receptor Ligand Specific activity Brain area Nonspecific
binding
Reference
Dopamine D; [3H]-spiperone 105 Ci/mmole Striatum Raclopride 1 цМ Lang et al., 1992
5-hydroxytryptamine [3H] -spiperone 105 Ci/mmole Frontal cortex Ketanserin 1 tiM Lang et al., 1992
5-HTJA
CCK [5H]-pCCK-8 75 Ci/mmole Frontal cortex Caerulein 100 nM Lang et al., 1995
and hippocampus
Benzodiazepine [3H]-flunitrazepam 90 Ci/mmole Frontal cortex Clonazepam 1 |iM Braestrup and Squires, 1977
binding assay (Bradford, 1976). Saturation curves were 
analyzed using non-linear least squares regression (Leath- 
erbarrow, 1987).
2.4. Hormonal studies
in all cases truncal blood was collected, serum was 
separated by centrifugation and samples were stored at 
—20°C until prolactin (PRL), thyrotropin (TSH) and 
growth hormone (GH) concentrations were determined 
from duplicate samples (0.1 ml) by specific radioim­
munoassays. The rat PRL, TSH and GH kits were gifts 
from NIH. PRL results are expressed in ng/ml of NIDKK- 
rPRL-RP-2 standard. TSH data are expressed in ng/ml of 
NIDKK-TSH-RP-2 standard. GH results are expressed in 
ng/ml of N1DKK-GH-RP-2 standard. The intra-assay 
coefficient of variation was less than 15%.
2.5. Statistics
Results are expressed in the tables as mean values ±  
S.E.M. Behavioral, hormonal and radioligand binding data 
were analyzed by means of one-way analysis of variance 
(ANOVA). Post hoc comparisons were performed using 
Newman-Keuls test. Pearson r correlation coefficient 
(simple linear correlation test) was employed for correla­
tion analysis.
3. Results
3.1. The selection o f  rats in the elevated plus-maze
Eighty handling-naive rats were used for the elevated 
plus-maze experiment. Forty five animals were selected for
the further studies. The remaining 35 were discarded since 
their behavior did not differ from the mean activity of all 
population. The selected 45 rats were divided into three 
subgroups according to their exploratory behavior (Table 2):
1) rats not leaving the closed arms; they were called 
‘anxious’ (8 animals);
2) rats with moderate exploratory activity, exploring 
mainly the central square located between open and 
enclosed arms and making less than two open arm entries 
per session; this group was named as ‘intermediate’ (30 
animals);
3) animals with high exploratory activity, making at 
least three open arm entries; they were called ‘non-anxi- 
ous’ (7 animals).
There were the significant correlations between several 
parameters of plus-maze exploration. The ratio between 
open and closed arm entries, a classical measure of anxiety 
in rodents (Pellow et al., 1985), was correlated with the 
open arm exploration time (r=0.89, PC0.01) and number 
of open arm entries (r=0.91, / ><0.01). A good correlation 
was also established between the number of closed arm 
entries and time spent in the central square (r=0.76, 
/*<0.01).
3.2. The radioligand binding studies in the selected rats
The ‘anxious’ rats had significantly lower affinity of 
5-HT2a receptors in the frontal cortex (Table 3) compared 
to home-cage controls and ‘non-anxious’ rats (F3 i8=2.30, 
P<0.05). The density of 5-HT2A receptors in the frontal 
cortex did not differ among the selected rats. The affinity 
and density of dopamine D2 receptors in the striatum was 
not affected by the exposure of rats to the plus-maze.
The ‘non-anxious’ rats had less [3H]pCCK-8 binding 
sites in the frontal cortex compared to the ‘anxious’
Table 2
The selection of rats according to their exploratory behavior in the elevated plus-maze (mean values ± S.E.M.).
Behavioral parameters ‘Anxious’ ‘Intermediate’ 'Non-anxious'
Number of attempts to enter into central square 2.8±0.5 6.0 ±0.7 5.1 ±0.7
Time spent in central square (sec) 0.5±0.3 69+4 98± 10
Time spent in open arm (sec) 0 8±3 38±8
Number of open arm entries 0 0.6 ±0.2 4.0±0.7
Number of closed arm entries
О
 
+ 
1 
О
5.5±0.5 10.4 ±0.8
Ratio open arm entries/closed arm entries 0 0.10+0.03 0.38+0.05
Table 3
Parameters of dopamine D,, 5-hydroxytryptamine 5-HTM, CCK and benzodiazepine receptors in selected rats (mean values
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S.E.M.).
Home-cage controls ‘Anxious’ 'Intermediate' 'Non-anxious'
1 HJ-spiperone binding in the frontal cortex {5-HT, 
K„ (nM)
B„,„ (fmol/mg protein)
0.98±0.12 
156±21
2.11 ±0.56" 
I80±43
1.32±0.21 
181 + 17
0.99±0.15‘ 
191 ±  14
[ ' H]-spiperone binding in the striatum (TO) 
K„ (nM)
B„„ (fmol/mg protein)
0.90±0.18 
221 ±8
0.57 ±0.09 
197110
0.80±0.09
199±9
0.86±0.21 
220 + 21
[ HJpCCK-8 binding in the frontal cortex 
K„ (nM)
B„„ (fmol/mg protein)
0.85±0.07
7.99±0.75
0.73 ±0.07 
8.89 ±0.95
0.81 ±0.07 
7.16±0.37
0.97 ±0.16 
6.31+0.46
[ H]pCCK-8 binding in ihe hippocampus 
K„ (nM)
В m., (fmol/mg protein)
0.52±0.07
3.80±0.37
0.70±0.07
5.96±0.44"
0.77±0.08
4.70+0.36
0.64±0.16
4.30±0.74
l'H]-flunitrazepam binding in the frontal cortex 
K„ (nM)
B,„„ (fmol/mg protein)
2.58±0.36
536±89
1 96±0.29 
581 ±62
2.39±0.36
621+28
1.97±0.36
556±113
“ /*<0.0*1 (compared to home-cage controls, Newman-Keuls test after significant one-way ANOVA); " P <0.05 (compared to 'anxious')
animals. However, this difference was not statistically 
significant. In the hippocampus, the ‘anxious’ animals had 
apparently higher density of CCK receptors than home- 
cage controls (F33l)=2.64, P < 0.05). The ‘non-anxious’ 
animals also tended to have less CCK receptors in the 
hippocampus compared to the ‘anxious’ counterparts. By 
contrast, the binding parameters of benzodiazepine re­
ceptors did not differ among the selected rats.
The correlation analysis revealed few weak, but signifi­
cant correlations between the plus-maze activity and 
radioligand binding parameters. The affinity of 5-HT2 
receptors and the number of CCKB binding sites in 
hippocampus negatively correlated with the exploratory 
behavior (/■=— 0.38, P < 0.05; r = — 0.31, P<0.05, respec­
tively).
3.3. The hormonal studies in the selected rats
The only significant change (Table 4) was established in 
the case of GH (F, 5g = 2.92, Ж 0.05). The ‘non-anxious’ 
animals had markedly lower levels of GH compared to 
‘anxious’ and intermediate rats.
4. Discussion
The present study is in good agreement with previous 
experiments confirming the significant variability of ex­
ploratory behavior of rats in the elevated plus-maze (Harro 
et al., 1990; Rägo et al., 1991). Among the 45 rats 
selected, we established a subgroup of animals eagerly 
exploring the open arms. The open arms are considered to 
be the most aversive parts of plus-maze (Pellow et al., 
1985). These ‘non-anxious’ rats performed three or more 
open arm entries per session. On the other hand, the other 
population of rats did not leave the enclosed arms at all. It 
is worth noting that these ‘anxious’ animals made several 
unsuccessful attempts to enter from the enclosed arm into 
the central square. Accordingly, the central square located 
between the opened and enclosed arms is too aversive a 
place for the ‘anxious’ rats to explore. The exploratory 
behavior of the ‘intermediate’ group represents the mean 
exploratory activity of whole population. Their behavioral 
activity was mainly restricted to the central square.
The results obtained from the radioligand binding 
studies are somewhat different from the previously pub­
lished data. Harro et al. (1990) found that the ‘anxious’ 
animals have a significantly increased density of CCK 
receptors in the frontal cortex and reduced amount of these 
receptors in the hippocampus. In the present study, the 
similar tendency was established in the frontal cortex. The 
‘anxious’ animals had more CCK binding sites compared 
to the ‘non-anxious’ counterparts, but this difference was 
not statistically significant. However, the situation was 
different in the hippocampus. Namely, we found increased 
number of [3H]pCCK-8 binding sites in the ‘anxious’
Table 4
Serum concentrations of anterior pituitary hormones in selected rats (mean values ±  S.H.M.).
Home-cage controls ‘Anxious’ 'Intermediate' ‘Non-anxious’
PRL (ng/ml) 17.1 ±4.4 12.7 + 3.0 13.1 ±2.2 5.5+1.0
GH (ng/ml) 15.7±3.4 27.1 ±4.9“ 24.5 ±2.8* 8.9+2.2
TSH (ng/ml) 1.3 ±0.4 2.2+0.6 1.3 ±0.2 1.3±0.4
* /*<0.05 (compared to non-anxious’ animals, Newman-Keuls test after significant one-way ANOVA)
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animals compared to home-cage controls. A similar, but 
much smaller elevation of CCK receptors was also observ­
able in the other selected groups, reflecting a possible link 
between the exploratory activity and density of CCK 
receptors in the hippocampus. The recent studies indicate 
that CCK receptors in the hippocampus belong to the 
CCKB (brain) receptor subtype (Honda et al., 1993). It is 
likely that the variations of exploratory behavior in rats are 
related in some extent to the differences in the density of 
CCKB receptors. However, Pratt and Brett (1995) did not 
detect any changes in the content of preproCCK mRNA in 
the frontal cortex and hippocampus after the plus-maze 
exposure. Nevertheless, the administration of inverse 
benzodiazepine agonist FG 7142 at the anxiogenic doses 
markedly increased the levels of preproCCK mRNA in 
both brain regions (Pratt and Brett, 1995). Despite the 
significantly distinctive behavior it could be that the plus- 
maze exposure is not enough strong stress to increase CCK 
binding sites in the brain of all rats. Therefore, only in the 
most susceptible animals exposure to the elevated plus- 
maze caused the marked elevation of CCK binding sites in 
the hippocampus.
Contrary to previous studies (Harro et al., 1990; Rägo et 
al., 1991), we did not find a link between the exploratory 
activity and density of benzodiazepine receptors in the 
frontal cortex. Two suggestions should be considered to 
explain this discrepancy. Firstly, the animals used in the 
earlier studies had a much higher level of basal anxiety 
(Harro et al., 1990; Rägo et al., 1991). Secondly, the 
animals in the previous experiments were kept in over­
crowded conditions (20-25 rats per cage) which is very 
stressful for experimental animals. Therefore, the high 
pre-experimental anxiety is a likely reason to explain the 
differences between the present and previous studies.
The ‘anxious’ rats displayed the reduced affinity of 
5-HT2A receptors in the frontal cortex compared to home- 
cage controls and ‘non-anxious’ rats. The background of 
this decrease remains to be established. However, this 
change can be explained in the light of recent findings. 
Namely, Rex et al. (1993, 1994) and Marsden et al. (1993) 
established that the exposure of rodents to the elevated 
plus-maze increased the release of 5-HT in the frontal 
cortex. Similar alterations are also described in the hip­
pocampus (Crawley and Corwin, 1994; File et al., 1993). 
Therefore, we are tempted to speculate that the reduced 
affinity of 5-HT2a receptors in the frontal cortex is related 
to the increased release of 5-HT in the ‘anxious’ rats.
Besides CCK and 5-HT, dopamine has also been shown 
to be involved in the regulation of anxiety (Glavin, 1993; 
Ladurelle et al., 1995). However, we did not find any 
significant modifications of dopamine D2 receptors in the 
striatum of selected rats. Accordingly, we were not able to 
establish a link between striatal dopamine receptors and 
exploratory behavior.
We investigated also the release of anterior pituitary 
hormones in relation to the exploratory behavior of rats. In 
the present study neither the exposure of rats to the
plus-maze nor distinctive exploratory activity correlated 
with the serum levels of anterior pituitary hormones 
prolactin and thyrotropin. Only the concentrations of 
growth hormone (GH) were significantly different in the 
selected rats. Namely, the ‘non-anxious’ rats had markedly 
lower levels of GH compared to the ‘anxious’ and inter­
mediate groups. Anterior pituitary hormones are regulated 
by a multitude of classic neurotransmitters like 5-HT and 
dopamine but also by neuropeptide transmitters (Tuomisto 
and Männistö, 1985). It has been shown that 5-HT 
stimulates the baseline release of GH and may be involved 
in the stress-induced GH elevation in man (Chamey et al., 
1987). CCK also participates in the regulation of GH. The 
activation of cholecystokinin CCKA (alimentary) receptors 
inhibits GH secretion while the activation of CCKB 
receptors caused an opposite effect (Männistö et al., 1994; 
Peuranen et al., 1994). Therefore, the augmented levels of 
GH in the ‘anxious’ animals might be caused by the 
increased activity of 5-HT and CCK in the brain.
In conclusion, the present study confirms significant 
individual differences in the exploratory behavior of rats. 
However, the variations in hormonal and receptoral levels 
between the selected groups are not as marked as in the 
behavioral studies. Nevertheless, the increased density of 
CCK receptors in the hippocampus and the reduced affinity 
of 5-HT2a receptors in the frontal cortex seem to be linked 
to the decreased exploratory activity of rats in the elevated 
plus-maze. The elevated plus-maze is a forced exploratory 
model (Belzung et al., 1994). Therefore, we suggest that 
the described neurochemical changes eare induced by the 
exposure of rats to the test situation and that they reflect 
the ‘state’ but not ‘trait’ anxiety. The background of 
changes in the content of GH remains to be elucidated, but 
it may be also related to the altered activity of 5-HT and 
CCK neurotransmission in the brain.
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Summary This study investigated the interplay of cholecystokinin (CCK) and endogenous opioid peptides in the 
regulation of anxiety. The acute administration of non-selective CCK agonist caerulein (1 and 5 цд/кд) and a selective 
CCKB receptor agonist BOC-CCK-4 (1,10 and 50 (ig/kg) induced a dose-dependent anxiogenic-like action in the plus- 
maze model of anxiety. BOC-CCK-4 displayed a similar efficacy with caerulein, indicating that the described effect was 
mediated via CCK8 receptor subtype. The opioid antagonist naloxone itself (0.5 mg/kg) did not change the exploratory 
activity of rats in the plus-maze. However, the combination of naloxone with the sub-effective doses of caerulein 
(1 (ig/kg) and BOC-CCK-4 (1 цд/кд) induced a significant inhibition of exploratory behaviour in rats. Accordingly, CCK 
and endogenous opioid peptides have an antagonistic role in the exploratory model of anxiety in rats.
INTRODUCTION
A growing body of evidence suggests the interaction of 
two neuropeptidergic systems -  cholecystokinin (CCK) 
and opioid peptides -  in the regulation of behaviour. The 
distribution of CCK in the brain parallels that of 
enkephalins and endorphins in the numerous brain 
regions.12 Moreover, CCK and opioid peptides are colo­
calized in the same neurons in discrete brain areas.’4 
Two different CCK receptor subtypes, namely CCKA and 
CCK,, receptors, are described in the central nervous sys­
tem.5 These receptors have been pharmacologically char­
acterized and cloned.6-8 It is suggested that CCK might 
function via the interaction with CCK  ^ receptors as an 
opioid antagonist in various behavioural models.9-" 
CCK  ^ receptor antagonists, but not CCKA antagonists, 
facilitate the antidepressant-like effect induced by opioid 
peptides in the conditioned suppression of motility test
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in mice.9 Moreover, the selective CCKg receptor anta­
gonist PD-134,308 has been shown to potentiate the 
rewarding effect of morphine in the place preference 
paradigm10 and to augment antinociception induced by 
opioid peptides.12
However, only a few studies13 have been performed on 
the role of opioid peptides in CCK-induced behavioural 
effects. CCK is implicated in the neurobiology of 
anxiety1415 and therefore an attempt was made to study 
the role of endogenous opioid peptides in CCK-induced 
anxiety in rats. A non-selective antagonist of opioid 
receptors (naloxone) was combined with sub-effective 
doses of CCK agonists caerulein and BOC-CCK-4. The 
possible anxiogenic-like action of these combinations in 
rats was studied in the elevated plus-maze.
MATERIALS AND METHODS
Animals
Male Wistar (Han/Kuo: WIST) rats (National Animal 
Centre, Kuopio, Finland) weighing 250 -300  g were kept 
four per cage in the animal house at 20 ± 2°C with a 12 h 
light/dark cycle (light on at 700 a.m.). Tap water and food
235
236 Kõks et al
pellets were available a d  libitum. There were 12 animals 
in each group.
The elevated plus-maze
The method initially suggested by Handley and Mithani16 
for the measurement of exploratory activity was 
employed in rats with some modifications.17 The appara­
tus consisted of two opposite open arms (50 x 10 cm) 
without side walls arid two enclosed arms (50 x 10 x 40 
cm) with side walls and end wall, extending from a central 
square (10 x 10 cm). The maze was elevated to a height of 
50 cm, and placed in a lit room. During a 5 min observa­
tion session the following measures were taken by an 
observer: 1) time spent in exploration of open part and 
open arms of plus-maze; 2) number of closed and open 
arm entries; 3) number of line crossings in open part; and
4) ratio between open and total arm entries. At the begin­
ning of the experiment an animal was placed into the cen­
tre of the plus-maze, facing toward a closed arm. An arm 
entry was counted only when all four limbs of the rat 
were within a given arm. The animals were brought into 
the experimental room 1 h before the experiment and 
were handling naive. After the injection of drugs the rats 
were placed in the single cages for 15 min before the plus- 
maze exposure. Each rat was tested only once.
Drugs
Caerulein (Sigma), BOC-CCK-4 (N-tert-butoxy-carbonyl- 
CCK-4; Sigma) and naloxone HCI (Sigma) were dissolved 
in physiological saline. Caerulein (1 and 5 ng/kg) and ВОС- 
ССК-4 (1, 10 and 50 ng/kg) were injected subcutaneously, 
naloxone (0.5 and 10 mg/kg) intraperitoneally. These drugs 
or saline were given 15 min before the experiment.
Statistics
Results are expressed as mean values ± SEM. The data of 
behavioural studies were analysed by one-way analysis 
of variance (ANOVA). Post hoc comparisons between 
individuell groups were performed by means of Newman- 
Keuls test with the Statistica for Windows software.
RESULTS
The subcutaneous administration of caerulein, a non- 
selective CCKA/CCK„ receptor agonist, induced a dose- 
dependent reduction of exploratory activity of rats in the 
elevated plus-maze. The behaviour of rats treated with 1 
Hg/kg of caerulein did not differ from that of saline- 
treated animals, whereas 5 p.g/kg of caerulein induced a 
statistically significant reduction in all studied parame­
ters (Fig. 1, time in open part F227 =  3.65, P <  0.05; open
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Fig. 1 The effects of caerulein, BOC-CCK-4 and naloxone upon 
the exploratory behaviour of rats in the plus-maze. All drugs were 
given 15 min before the experiment, naloxone was injected 
intraperitoneally, caerulein and BOC-CCK-4 subcutaneously.
' P <  0.05, Newman-Keuls after significant ANOVA, compared 
with saline-treated animals.
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arm entries F. 27 =  3.89, P <  0.05; ratio between open and 
closed arm entries F227 =  3.62, P<  0.05). The higher dose 
of caerulein eilso induced a significant reduction in line 
crossings (from 28 ± 3 to 10 ± 2, F227 =  3.90, P <  0.05) and 
closed arm entries (from 6.9 ± 0.7 to 3.2 + 0.7, F227 =  5.26, 
P  <  0.05). The treatment with BOC-CCK-4, a selective 
CCKB receptor agonist, also induced a dose-dependent 
reduction of exploratory behaviour of rats in the plus- 
maze paradigm. One |ig/kg of BOC-CCK-4 did not mod­
ify the behaviour of rats if compared with control rats. 
However, the higher doses of BOC-CCK-4 (10 and 50 
Hg/kg) induced a statistically significant reduction in the 
behavioural measures believed to reflect anxiety in 
rodents: the number of open arm entries (F3 56 =  4,08, P<  
0.01) and ratio between open and total arm entries (F3 56 = 
3.14, P  <  0.05). The reduction of line crossings (F3 56 =  
2.51, P =  0.067) and closed arm entries (F356 =  2.50, P =  
0.069) did not reach the statistically significant level.
The administration of naloxone (0.5 and 10 mg/kg) did 
not modify the exploratory behaviour of rats. 
Nevertheless, 10 mg/kg of naloxone, unlike the lower 
dose (0.5 mg/kg), tended to reduce the activity of rats in 
the plus-maze without significant differences.
The combination of naloxone (0.5 mg/kg) with the sub­
effective dose of caerulein (1 |ig/kg) induced a statisti­
cally significant reduction of exploratory behaviour of 
rats (Fig. 2, line crossings F346 =  2.85, P <  0.05; time in 
open part F346 - 3.62, P <  0 05). The same was true with 
the combination of naloxone with the sub-effective dose 
of BOC-CCK-4 (1 M g/kg) (line crossings F330 =  7.69, P < 
0.01; time in open part F330 =  1 1.79, P <  0.01; open arm 
entries F3J0 =  3.45, P <  0.05; time in open arm F330 =  2.95, 
P <  0.05; closed arm entries F330 =  8.63, p <  0.01; ratio 
between open and closed arm entries F3 30 =  2.95, P < 
0.05). In fact, the combination of naloxone with the CCKB 
receptor agonist induced much stronger inhibition of 
exploratory activity compared with the combination of 
opioid antagonist and caerulein.
DISCUSSION
A recent study established that the anxiogenic-like 
action of caerulein, a non-selective agonist of 
CCKA/CCKB receptors, in the elevated plus-maze is 
dependent on pre-experimental stress in rats.15 The 
administration of caerulein induced the anti-exploratory 
effect only in rats not adapted to handling, i.e. CCK ago­
nist increased neophobia. In the present study, two ago­
nists of CCK receptors, caerulein and BOC-CCK-4, with 
different selectivity for CCKB receptor subtype, caused a 
similar and dose-dependent reduction of exploratory 
behaviour in rats. Accordingly, this anxiogenic-like 
action of CCK agonists in the plus-maze was mediated 
via the CCKj receptor subtype.
The administration of the opioid antagonist naloxone 
at a low dose (0.5 mg/kg) did not affect the exploratory 
behaviour of rats. However, the higher dose (10 mg/kg) 
of naloxone tended to reduce the activity of rats. This 
trend in the action of naloxone could be explained in the 
light of data showing that it blocks not only ц-opioid 
receptors, but also b- and к-receptors.'8 Indeed, Motta 
and Brandao19 have shown that the systemic administra­
tion of morphine at low doses or its injection into the 
dorsal periaquaductal grey induced anxiolytic-like action 
in the elevated plus-maze. Naloxone at low doses 
reversed the anxiolytic-like effect of morphine. Privette 
and Terrian20 found that the administration of к-opioid 
agonists, U-50, 488H and U-69,593, induced a strong 
anxiolytic-like action in the elevated plus-maze. This 
action of к-opioid agonists is reversed by naloxone, also 
suggesting an opioid receptor site of action.20 Therefore, 
it is likely that naloxone administered at low doses inter­
acts only with ц-opioid receptors, whereas at higher 
doses the interaction with к-opioid receptors is also 
involved. The co-administration of naloxone (0.5 mg/kg) 
with the sub-effective doses of caerulein and BOC-CCK-
4 induced a potent anxiogenic-like action in the elevated 
plus-maze. This finding is apparently in favour of an 
antagonistic interplay between CCK and endogenous 
opioid peptides in the regulation of anxiety.
There are several studies showing the negative interac­
tion between CCK and endogenous opioid peptides in 
the regulation of pain sensitivity. However, as in the pre­
sent work, the action of CCK was dependent on the pre- 
experimental stress of rats. Wiertelak et al21 have shown 
that CCK antagonizes morphine-induced antinocicep­
tion only in the novel, but not in the familiar environ­
ment. This finding was confirmed by Lavigne et al22 
demonstrating that CCK antagonists devazepide and L- 
365,260 enhanced morphine-induced analgesia only in 
non-acclimatized rats exposed to the novel environment. 
Therefore, it is likely that even in the case of pain regula­
tion the interplay between CCK and endogenous opioid 
peptides is actually dependent on the level of anxiety. 
This suggestion is supported by a recent study by 
Benedetti et al23 who found that nocebo-induced hyper­
algesia was reversed dose dependency by the CCK 
antagonist proglumide, but not by naloxone. As the 
nocebo procedure represents an anxiogenic stimulus it is 
likely that nocebo hyperalgesia may be due to a CCK- 
dependent increase in anxiety.
According to the hypothesis of Wiertelak et al,21 the 
environmental stimuli that signal the occurrence of aver­
sive or dangerous events activate endogenous opioid 
analgesia systems. The signals for safety (the non-occur­
rence of aversive events) produce the opposite effect and 
inhibit environmentally produced analgesia. Wiertelak et 
al21 believe that CCK is a mediator of that kind o f safety
©  Harcourt Brace and Co. Ltd 1998 Neuropeptides (1998) 32(3), 235-240
238 Kõks e t a l
20 - I
к
Sal Nal Caer С4 Nal+Nal+ 
caer C4
J
Sal Nal Саег C4 Nal+Nal+ 
саег С4
JL
Iй
Sal Nal Caer С4 Nal+Nal+ 
caer C4
150 -1
Г 1 00  -
50 -
T
I
й ш
Sal Nal Саег С4 Nal+Nal+ 
саег C4
Ё  20
.E 10 -Ш1
Sal Nal Caer C4 Nal+Nal+ 
caer С4
caer С4
Fig. 2 The action of sub-effective doses of caerulein (1 цд/кд) and ВОС-ССК-4 (1 цд/кд) alone and in combination with naloxone (0.5 
mq/kq) in the elevated plus-maze. Drugs were administered 15 min before the experiment. Sal, saline; Nal, naloxone; Caer, caerulein; C4, 
BOC-CCK-4. *P< 0.05, Newman-Keuls after significant ANOVA, compared with saline-treated animals; +, P <  0.05, Newman-Keuls after 
significant ANOVA, compared with BOC-CCK-4-treated animals.
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signal. However, the present study is not in favour of that 
statement, as CCK apparently increases anxiety in the 
novel environment and the anxiogenic-like action of 
CCK was potentiated by the opioid antagonist naloxone. 
Therefore, CCK is rather signalling that the novel 
environment is unsafe and aversive.
In fact, most studies have explored the action of CCK 
agonists and antagonists on the behavioural effects of 
morphine and endogenous opioid peptides, and few stud­
ies have been devoted to the investigation of endogenous 
opioid peptides and their receptors in the behavioural 
effects of CCK. However, a similar antagonistic interac­
tion between CCK and opioid peptides was described by 
Riley and Melton.11 Namely, the administration of nalox­
one strongly potentiated CCK-induced conditioned taste 
aversion. However, this action of CCK was mediated via 
ССКЛ receptors. Moreover, the selective 5-opioid antago­
nist naltrindole, unlike naloxone, did not potentiate the 
aversive learning induced by CCK.1’ Accordingly, the 
antagonistic interaction between CCK and opioid pep­
tides seems to occur at various levels: CCKA receptors 
located in the periphery are likely targets for food aver­
sion, whereas CCKj, receptors in the brain are responsible 
for the aversion toward environment.
There are some hints that the interplay between CCK 
and opioid peptides may also contribute to the mecha­
nisms of human anxiety. Patients suffering from panic 
disorder have an increased sensitivity toward the panico- 
genic-like action of CCK-4,14 but they also seem to have a 
reduced tone of endogenous opioid system reflected as 
reduced concentrations of ß-endorphin in the cere­
brospinal fluid.24
In conclusion, CCK and endogenous opioid peptides 
have an opposite role in the behavioural response of ani­
mals toward the novel environment. The simultaneous 
stimulation of CCKB receptors and the blockade of 
fi-opioid receptors apparently increase anxiety in rats. 
Endogenous opiod peptides interacting with ц-opioid 
receptors seem to be the endogenous antagonists of 
CCK-induced anxiety
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A bstract
The administration of paroxetine (0.5-8 mg/kg), a selective 5-HT reuptake inhibitor, induced a dose- 
dependent reduction of exploratory activity of rats in the motility test. In the elevated plus-maze paroxetine 
was less effective, only 6 m g/kg of paroxetine decreased the exploratory behaviour of rats. The doses of 
paroxetine (2-8 m g/kg) reducing the exploratory activity in the motility test increased the density of CCK 
receptors in the frontal cortex, but not in the hippocampus. The treatment of rats with the CCKU receptor 
antagonist LY288.513 (0.01-1 mg/kg) did not change the exploratory activity. However, the reduction of 
exploratory activity induced by the low dose of paroxetine (2 mg/kg), but not by the higher dose (8 mg/kg), 
was dose-dependently reversed by the administration of LY288,513. Moreover, LY288.513 did not affect the 
anti-exploratory action of paroxetine (8 m g/kg) in the elevated plus-maze. Diazepam at doses (0.5-1.0 m g/kg) 
not suppressing the locomotor activity did not change the anti-exploratory action of paroxetine in the motility 
test. It is likely that the anti-exploratory action of a low dose of paroxetine (2 mg/kg) is not related to the 
increase in anxiety, but rather to the reduction of exploratory drive. Evidence exists that this effect of 
paroxetine is mediated via the activation of CCK-ergic transmission
Received 7 September 1998; Reviewed 9 November 1998; Revised 1 December 1998; Accepted 6 December 1998 
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Introduction
There is a growing body of evidence that cholecystokinin 
(CCK) and 5-hydroxytryptamine (5-HT) interact in the 
regulation oi behaviour. The administration of chole­
cystokinin tetrapeptide (CCK-4), an agonist of CCKB 
(brain subtype, CCK2) receptors, induces an anxiogenic- 
like action in the elevated plus-maze, and this behavioural 
action of CCK agonist is accompanied by the increased 
release of 5-HT in the cerebral cortex (Rex et al., 1994). 
On the other hand, CCKB receptor antagonist L365,260 
causes the opposite effect and antagonizes the behavioural 
and neurochemical action of CCK-4 (Rex et al., 1994). 
Peripherally administered CCK-8 reduces the food intake 
and elevates the levels of 5-HT in the hypothalamus 
(Voigt et al„ 1998). The stimulation of somatodendritic 5- 
HT autoreceptors by 5-HT,A receptor agonist 8-OH- 
DPAT reverses CCK-8 induced satiety and CCK-4 caused 
anxiety (Poeschla et al., 1992; Rex et al., 1997). However, 
it should be noted that the anxiogenic-like action of CCK
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is mediated via the CCKB receptor subtype, whereas 
CCKA (peripheral subtype, CCK,) receptors are respon­
sible for CCK-induced satiety (Shlik et al., 1997). The 
application of CCK-4 to the brain membranes increases 
the density of 5-hydroxytryptamine 5-НТг receptors in 
the frontal cortex (Agnati et al., 1983). Therefore, it is not 
surprising that the 5-HT2 receptor antagonist deramci- 
clane antagonizes the anxiogenic-like action of caerulein, 
an unselective CCKA/CCKB receptor agonist (Gacsalyi et 
al., 1997).
However most experiments have studied a role of 5- 
HT in the action of CCK receptor agonists and antago­
nists, whereas very little attention is paid to the opposite 
interaction. Nevertheless, it has been shown that 5-HT 
can increase the release of CCK in the cerebral cortex and 
nucleus accumbens (Raiteri et al., 1993). The acute 
administration of alaproclate, the 5-HT reuptake inhibitor, 
significantly elevates the levels of CCK in the cingulate 
cortex and periaquaductal grey (Rosen et al„ 1995). 
Moreover, the exposure of rats to the novel aversive 
environment clearly increases the release of 5-HT in the 
frontal cortex and hippocampus (File et al., 1993; Rex et 
al., 1994). The administration of fluoxetine, the 5-HT 
reuptake inhibitor, dose-dependently reduces the ex­
ploratory behaviour of rats in the elevated plus-maze
2 S. Kõks et al.
(Handley and McBlane, 1993). Handley and McBlane 
(1993) have considered the anti-exploratory action o f "  
fluoxetine as the anxiogenic-like action. Den Boer and 
Westenberg (1996) have shown in the clinical studies that 
the acute administration of 5-HT reuptake inhibitors may 
increase anxiety in patients suffering from anxiety 
disorders. Therefore, the aim of present experiments was 
to clarify a possible role of CCK in the anxiogenic-like 
action of drugs increasing 5-HT-ergic transmission. For 
that purpose a selective 5-HT reuptake inhibitor par­
oxetine was chosen. The behavioural effects of paroxetine 
were analysed in the motility box and elevated plus-maze. 
These two behavioural tests were selected to distinguish 
whether paroxetine-induced inhibition of exploratory 
behaviour is due to the increase in anxiety or the reduction 
of exploratory drive. Moreover, the action of paroxetine 
was studied on the parameters of CCK binding in the 
frontal cortex and hippocampus. Also the influence of 
CCKB antagonist LY268,513 and diazepam, a benzo­
diazepine anxiolytic drug, on the behavioural effects of 
paroxetine was examined.
M aterials and m ethods 
Anim als
Male Wistar (Han/Kuo) rats (National Animal Centre, 
Kuopio, Finland) weighing 200-220 g were kept in the 
animal house at 20 +  2 °C in a 12-h light/dark cycle (light 
on at 07:00 hours). Tap water and food pellets were 
available ad libitum. All animal procedures were approved 
by University of Tartu Animal Care Committee in 
accordance with the European Communities Directive of 
24 November 1986 (86/609/EEC). The animals were 
kept in the animal house at least 2 wk before the beginning 
of experiment.
M aterials
Paroxetine, a selective 5-HT reuptake inhibitor, was 
provided by SmithKline and Beecham (UK). LY288,513 
[fr«ns-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-l-pyrazo- 
lidinecarboxamide], an antagonist of CCKB receptor, was 
kindly donated by Eli Lilly & Co. (USA). Paroxetine was 
dissolved in saline, whereas LY288,513 and diazepam 
(Sigma, USA) were suspended in 1% Tween-80 (Ferak, 
Germany) solution in saline. [Propionyl-sH]propionyl- 
ated-CCK-8-sulphated ([3H]pCCK-8) was obtained from 
Amersham Radiochemicals (UK). The other chemicals for 
radioligand-binding studies (caerulein, Hepes (N-[2- 
hydroxyethylJpiperazine-N'-[-2-ethane-sulphonic acid)), 
NaCl, MgCl2, KC1 and EDTA ([ethylenediamine-tetra- 
acetic acid]) were purchased from Sigma (USA).
Behavioural testing
The animals were brought into the experimental room 1 h 
before the experiment. The rats were new to handling and 
were not adapted to the experimental situation. Each rat 
was used only once. All experiments were carried out 
between 14:00 and 19:00 hours. Paroxetine, diazepam 
and LY288,513 were given 30 min before the beginning 
of studies.
M o tility  test
Exploratory activity of rats was measured by means of 
photoelectric motility boxes (448 x 448 x 450 mm) con­
nected to a computer (TSE Technical & Scientific Equip­
ment GmbH, Germany). Animals, new to the test situation 
were placed singly into the apparatus. Time in exploration 
(s), distance of exploration (in metres), number and 
duration of rearing were registered in 5-min intervals 
during the 15-min observation period.
Elevated plus-maze
The method initially suggested by Handley and Mithani 
(1984) for the measurement of exploratory activity was 
employed in rats with some modifications (Pellow et al., 
1985). The apparatus consisted of two opposite open 
arms (50 x  10 cm) without side walls and two enclosed 
arms (50 x  10 x  40 cm) with side walls and end wall, 
extending from a central square (10 x 10 cm). The maze 
was elevated to the height of 50 cm, and placed in a lit 
room. During a 5 min observation session the following 
measures were taken by an observer: (1) time spent in 
exploring of open part (central square and open arms) of 
plus-maze; (2) time spent in open arm; (3) number of 
closed and open arm entries; (4) number of line crossings 
in open part; and (5) ratio between open and total arm 
entries. At the beginning of experiment an animal was 
placed into the centre of plus-maze, facing towards a 
closed arm. An arm entry was counted only when all four 
limbs of the rat were within a given arm.
I*H]pCCK-8 binding assay
The animals were decapitated 30 min after the injection of 
various doses of paroxetine (0 .5-16  m g/kg i.p.). After 
decapitation the brains were quickly dissected on ice. The 
binding studies were performed in the frontal cortex (also 
containing the anterior cingulate and frontoparietal cor­
tex) and hippocampus. These brain structures were 
selected according to previous studies since the most 
prominent neurochemical changes due to the reduced 
exploratory behaviour have been found in these brain
Role o f CCK in the anti-exploratory action o f  paroxetine 3
300 -I
I
oZOO - I 
о  
E
Оо _o
£Z 10° ^
m
В 
h-
0 J  ,-------- Ih-------1------ Р - - М ТЛ., ------ -
0 10 100 1000 10000
Dose fig/kg
so
a 20 -
0  J  t------- \\—  I - r  I4 I WMI
0 10 100 1000 10000
Doc* Mg/kg
E 20'
100 1000 
Do«* pg/kg
E 20 -
100 1000 
Do** pg/kg
Figure 1. The effect of paroxetine (0.5-8 mg/kg), diazepam (0.5-2.5 m g/kg) and LY288.513 (0.01-1 m g/kg) on the exploratory 
activity of rat in the motility box. ’ p <  0.05 compared to saline (paroxetine) or vehicle-treated (LY288.513, diazepam) rats,
Tukey HSD test after the significant one-way ANOVA). Vehicle for LY288,513 and diazepam was 1% Tween-80 solution in 
saline.
regions (File et al., 1993a; Harro et al., 1995; Kõks et al., 
1997; Rex et al., 1994). Brain tissues were homogenized in 
20 volumes of ice-cold 50 т м  Tris-HCl (pH 7.4 at 4 °C) 
using a Potteir-S glass-Teflon homogenizer (1000 rpm, 12 
passes). The membranes were washed twice in the same 
buffer by centrifugation (48000 g  for 20 min) and re­
suspension. After the last centrifugation, the crude brain 
membranes were homogenized in Hepes buffer (10 т м  
Hepes; 130 т м  NaCl; 5 т м  KCl; 1 т м  MgCl2; 1 т м  
EDTA; pH 6.5 adjusted with 1 n  NaOH) containing 
bovine serum albumin (0.5 mg/ml). The parameters of 
CCK receptors were determined in the presence of 
0.05—2.4 пм [®H]pCCK-8 (specific activity 79 Ci/mmol) 
at 23 °C in a total incubation volume of 0.5 ml. Caerulein 
(100 пм) was added to determine the nonspecific binding. 
The incubation was terminated after 120 min by the rapid 
filtration over Whatman GF/B filters presoaked with the 
bovine serum albumin (0.5 mg/ml). The filters were 
washed with 3 x  3 ml of ice-cold Hepes buffer. In the 
separate study paroxetine (0.01-1 т м ) was added to the 
incubation medium to reveal the direct interaction of 
paroxetine with CCK-binding sites in the cerebral cor­
tex. The protein content was measured according to a 
dye-binding assay (Bradford, 1976). Saturation curves 
were analysed using nonlinear least squares regression 
(Leatherbarrow, 1987).
Statistics
Results are expressed as mean values +  s.e .m . The be­
havioural studies were analysed using one-way analysis 
of variance (ANOVA). Post hoc comparisons between 
individual groups were performed by means of Tukey 
HSD test using the Statistica for Windows software. The 
data of radioligand-binding experiments were assessed by 
means of Student's t test.
Results
The administration of paroxetine (0.5, 2, 4, 8 m g/kg) 
induced a dose-dependent reduction of exploratory 
activity of rats in the motility test (Figure 1). Paroxetine 
significantly reduced the frequency of rearing (FA 51 =  
3.50, p <  0.05) and time spent in rearing 61 =  3.02,
LY 2*8,513
LY 2*t,S13
LY 2М.51Э
DM£«pam
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F igure 2. The effect of paroxetine (0.5-16 m g/kg) on the 
parameters of CCK binding in the frontal cortex and 
hippocampus. Ka, dissociation constant in пм; BmiI. the 
apparent number of binding sites in fmol/mg protein.
* p < 0.05 (compared to saline-treated rats, Student's t test).
p <  0.05). Paroxetine also tended to inhibit the other 
parameters of exploratory activity in the motility test. 
However, these changes were not statistically significant. 
The same doses of paroxetine tended to elevate the 
density of CCK-binding sites in the frontal cortex (also 
including the cingulate and frontoparietal cortex), but not 
in the hippocampus (Figure 2). The addition of paroxetine 
(0.01—1 тм ) to the brain membranes did not modify CCK 
binding in the cerebral cortex (data not shown). Dif­
ferently from the motility test, only S m g/k g of par­
oxetine inhibited the exploratory behaviour of rats in 
the elevated plus-maze. Paroxetine decreased time spent 
in open part (E, 43 =  2.63, p < 0.05), number of line 
crossings (F- 43 =  2.97, p <  0.05) and closed arm entries 
(F5 a3 =  3.18, p <  0.05) (Table 1).
LY268,513 (0.01-1 mg/kg), a CCKB receptor antag­
onist, did not affect the behaviour of rats in the motility 
test (Figure 1). Nevertheless, the pretreatment of rats with 
LY288,513 dose-dependently antagonized the anti- 
exploratory action of paroxetine (2 m g/kg; time in 
locomotion F4 36 =  2.8, p <  0.05; frequency of rearing 
Fi3 i  =  3.83, p < 0.05; time in rearing f4 35 =  4.13, 
p <  0.01) (Figure 3). The combination of CCKB receptor 
antagonist with the higher dose of paroxetine (8 m g/kg) 
did not reverse the behavioural suppression induced by 
5-HT reuptake inhibitor (Figure 4). In addition, LY288.513 
(0.01-1 mg/kg) did not antagonize the anti-exploratory 
action of paroxetine (8 mg/kg) in the elevated plus-maze 
(data not shown).
The administration of the benzodiazepine agonist 
diazepam (0.5-2.5 m g/kg) also suppressed the explora­
tory activity of rats at the highest dose (2.5 mg/kg) 
(Figure 1, time spent in exploration F3 зг =  3.33, p <  
0.05; the exploration distance F3 32 =  2.97, p <  0.05).
Table X. The effect of paroxetine (0.5-16 m g/kg) on the exploratory activity of rats in the elevated plus-maze
Time in Time in Ratio
open part No. of line No. of open open arm No. of closed open: total
Treatment (s) crossings arm entries (s) arm entries arm entries
Saline 124 ± 1 3 24 ± 2 .7 1 .6 ± 0 .5 1 8 ± 6 6 .0 ± 0 .5 1 8 ± 5
Paroxetine 114 ±  18 21 ± 3 .8 1.4 ± 0 .3 21 ± 5 5.1 ± 0 .9 19 +  4
(0.5 m g/kg) 
Paroxetine 131 ± 1 7 25 ± 5 .5 1.3 ± 0 .6 1 9 ±  9 6 .0 ±  1.2 1 0 ± 4
(2 m g/kg) 
Paroxetine 114 ±  15 1 9 ± 3 .9 1 .3 ± 0 .7 13 ± 8 4.4 ± 0 .7 12 ± 7
(4 m g/kg) 
Paroxetine 66 ±16* 8 ±1.9* 0.3 ± 0 .3 4 ± 3 1 .9±0.4* 6 ± 4
(8 m g/kg) 
Paroxetine 85 ± 1 3 14 ±  4 0.5 ± 0 .4 1 8 ±  13 4 .0 ±  1.2 7 ± 5
(16 m g/kg)
' p  <  0.05 (Tukey HSD test after the significant one-way ANOVA, compared to  saline-tteated rats).
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Figure 3. The effect of LY288.513 (0.01-1 m g/kg) on the anti-exploratory action of paroxetine (2 m g/kg). *p <  0.05 (compared 
to saline +  vehicle-treated rats); +  , p <  0.05 (compared to paroxetine-treated rats, Tukey HSD test after the significant one-way 
ANOVA). CONT. saline +  vehicle-treated rats; PRX2, paroxetine 2 m g/kg; LY, LY288.513.
However, the combination of diazepam at doses not 
suppressing exploratory behaviour (0.5-1.0 mg/kg) with 
paroxetine (2 m g/kg) did not modify the anti-exploratory 
action of 5-HT reuptake inhibitor (Figure 5).
Discussion
The administration of paroxetine, a selective inhibitor of 
5-HT reuptake, induced a significant suppression of 
exploratory activity of rats in the motility test. Already 
2 m g/k g of paroxetine inhibited the frequency of rearing 
and time spent in rearing. However, the selectivity of 
paroxetine in inhibition of rearing depends on the basal 
exploratory activity of control animals. In the experiments 
where the activity of rats was higher, this dose of 
paroxetine also reduced the other parameters of ex­
ploratory behaviour, namely time spent in exploration 
and distance of exploration. Nevertheless, the frequency 
of rearing and time spent in rearing are the most sensitive 
parameters in revealing the anti-exploratory action of 
paroxetine in the motility test. Moreover, paroxetine was 
apparently less potent in the reduction of exploratory 
activity of rats in the elevated plus-maze. Only 8 m g/kg  
of paroxetine decreased the exploratory behaviour of
animals. The anti-exploratory action of paroxetine in the 
elevated plus-maze was accompanied by the decreased 
number of closed arm entries, reflecting the suppression of 
locomotor activity. The existing experimental data sup­
port the role of 5-HT in the regulation of anxiety. 
Handley and McBlane (1993) have shown that the 
administration of fluoxetine, the 5-HT reuptake inhibitor, 
induces the anxiogenic-like action in the rat elevated plus- 
maze. The administration of paroxetine produced an 
anxiogenic-like profile in the rat two-compartment ex­
ploration test (Sanchez and Meier, 1997). The exposure of 
rats to the aversive environment clearly increases the 
release of 5-HT in the frontal cortex and hippocampus 
(File et al., 1993; Rex et al., 1994). Nevertheless, the 
present behavioural study is in disagreement with the 
data since the anti-exploratory action of paroxetine is 
related to the decrease of exploratory drive rather than to 
the increase in anxiety.
Rosen et al. (1995) have shown that 5-HT reuptake 
inhibitor alaproclate increases the levels of CCK in the 
cingulate cortex and periaquaductal grey. The direct 
application of 5-HT to the neurons of cerebral cortex and 
nucleus accumbens evoked the release of CCK (Raiteri et 
al., 1993). In the present study paroxetine elevated the
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Figure 4. The effect of LY288.513 (0.01-1 m g/kg) on the anti-exploratory action of paroxetine (8 m g/kg). ’ p <  0.05 (compared 
to saline +  vehicle-treated rats, Tukey HSD test after the significant one-way ANOVA). CONT. saline +  vehicle-treated rats; 
PRX8, paroxetine 8 m g/kg ; LY, LY288.513.
number of CCK-binding sites in the frontal cortex, but not 
in the hippocampus. The stressful manipulations in rats 
are shown to increase the density of CCK receptors and 
mRNA levels of preproCCK in the frontal cortex (Harro 
et al., 1995; Pratt and Brett, 1995). The social isolation of 
rats for 7 d induced an anxiogenic-like action and elevated 
the number of CCK receptors in the frontal cortex, but not 
in the hippocampus (Vasar et al., 1993). Therefore, it is not 
surprising that the pretreatment of rats with the CCKB 
receptor antagonist LY288,513 dose-dependently re­
versed the anti-exploratory action of paroxetine 
(2 mg/kg). This in line with the study of Matto et al. 
(1996) showing the ability of the CCKB receptor an­
tagonist L365.260 to antagonize the anti-exploratory 
effect of the 5-HT reuptake inhibitor citalopram in the 
elevated plus-maze. The data support the hypothesis that 
the administration of 5-HT reuptake inhibitors increases 
CCK-mediated neurotransmission in the brain. The anta­
gonism of LY288,513 against paroxetine seems to be a 
specific since the CCKB receptor antagonist does not 
increase the exploratory activity per se. Nevertheless, 
LY288,513 did not block the effect of the higher dose of 
paroxetine (8 m g/kg) showing a difference in the action 
of two doses of 5-HT reuptake inhibitor. This discrepancy
could be explained by the fact that paroxetine at higher 
doses induces a more pronounced increase in the con­
centration of 5-HT in the synaptic cleft, masking a 
possible interaction of a drug with CCK. Differing from 
the present study, Harro et al. (1997) did not find changes 
in the density of CCK receptors or in the content of CCK- 
related peptides after long-term treatment with various 
antidepressant drugs, including 5-HT reuptake inhibitors. 
However, they analysed the action of long-term admin­
istration of antidepressant drugs, whereas the effect of 
acute treatment was not examined.
In conclusion, the selective serotonin reuptake inhibitor 
paroxetine induces a clear anti-exploratory effect in the 
motility boxes. However, the above-described be­
havioural studies do not reflect the increase in anxiety 
after the acute treatment with paroxetine. This statement 
is supported by the findings that paroxetine did not cause 
the anxiogenic-like action in the elevated plus-maze and 
that diazepam, a potent anxiolytic drug, did not antag­
onize the anti-exploratory action of paroxetine in the 
motility test. Therefore, it is likely that paroxetine reduces 
the exploratory drive in rats. This effect of paroxetine 
seems to be mediated via the increase in CCK-ergic 
neurotransmission.
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BOC-CCK-4, CCKg receptor agonist, 
antagonizes anxiolytic-like action of 
morphine in elevated plus-maze
S. Kõks,12 A. Soosaar,1 V. Võikar,1 M. Bourin,3 E. Vasar1
'Department ol Physiology, University ot Tartu, Estonia ’ Institute o( Molecular and Cell Biology, University ol Tartu, Estonia ’ Laboratory of Pharmacology, 
University of Nantes, France
Summary This study investigated a role ot cholecystokinin (CCK) in the anxiolytic-like action ot morphine, an agonist 
of ц-opioid receptors, in the rat plus-maze model ot anxiety. The acute administration of morphine (1 mg/kg) induced a 
significant increase of exploratory activity in the plus-maze, but did not affect the locomotor activity in the motility test. 
The higher dose of morphine (2.5 mg/kg) tended to decrease the locomotor activity and, therefore, did not cause the 
anxiolytic-like action in the plus-maze. The other drugs (naloxone, BOC-CCK-4, L-365,260) and their combinations with 
morphine (0.5-1 mg/kg) did not affect the locomotor activity of rats. The opioid antagonist naloxone itself (0.5 mg/kg) 
did not change the exploratory activity in the plus-maze, but potently antagonized the anxiolytic-like action of morphine 
(1 mg/kg). An agonist of CCKg receptors BOC-CCK-4 (1-50 цд/кд) induced a dose-dependent anxiogenic-like action in 
the plus-maze. Nevertheless, only one dose of BOC-CCK-4 (10 цд/кд) completely reversed the action of morphine. 
Also, one dose of CCKB receptor antagonist L-365,260 (10 цд/кд) was effective to modify the behaviour of rats in the 
elevated plus-maze. Namely, this dose of L-365,260 increased the ratio between open and total arm entries, a 
behavioural measure believed to reflect the anxiolytic-like action in the elevated plus-maze. The combination of 
L-365,260 (100 цд/кд) with the sub-effective dose of morphine (0.5 mg/kg) caused the anxiolytic-like action in the 
plus-maze not seen if the drugs were given alone. In conclusion, morphine induces a potent anxiolytic-like action in 
the elevated plus-maze and CCK is acting as an endogenous antagonist of this effect of morphine.
IN TR O D U C TIO N
Recent studies suggest that the administration of opioid 
receptor agonists potently decreases anxiety in the rat 
plus-maze model. Motta and Brandao1 have shown that 
the systemic treatment with morphine, an agonist of 
ц-opioid receptors, at low doses or its injection into the 
dorsal periaquaductal gray induced anxiolytic-like action 
in the plus-maze. An antagonist of opioid receptors 
naloxone at low doses reversed the anxiolytic-like effect 
of morphine. Privette and Terrian2 have found that the 
administration of к opioid agonists, U-50, 488H and
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U-69, 593, induces a strong anxiolytic-like action in the 
elevated plus-maze. This action of к opioid agonists is 
reversed by naloxone, also suggesting an opioid receptor 
site of action2.
The behavioural effectiveness of opioid receptor 
agonists seems to be dependent on the activity of 
cholecystokinin (CCK), a neuropeptide widely dis­
tributed in the mammalian brain. The distribution of 
CCK in the brain parallels that of endopioid peptides in 
the various brain regions3'4. Moreover, CCK and endo­
pioid peptides are colocalized in the same neurons in dis­
crete brain areas.5'6 Two different CCK receptor subtypes, 
respectively ССКЛ (peripheral subtype) and CCK  ^ (brain 
subtype) receptors, are described in the central nervous 
system /8 It is suggested that CCK might function via the 
interaction with CCK, receptors as an endogenous 
opioid antagonist in various behavioural models.'" 
CCK, receptor antagonists, but not CCKA antagonists,
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facilitate the antidepressant-like effect induced by opioid 
peptides in the conditioned suppression of motility test 
in mice9. Moreover, the selective CCK, receptor anta­
gonist PD-134,308 is shown to potentiate the rewarding 
effect of morphine in the place preference paradigm10 
and to augment antinociception induced by endopiod 
peptides.12 The CCK, receptor antagonists L-365,260 and 
PD-134,308 reversed the place aversion induced by 
naloxone in morphine dependent rats, whereas the CCKA 
receptor antagonist devazepide was ineffective.13
CCK is also implicated in the neurobiology of 
anxiety.14 Recently, we have found that the pretreatment 
with the opioid antagonist naloxone potentiates the 
anxiogenic-like action of CCK agonists in the plus- 
maze.15 Therefore, in the present study an attempt was 
done to show that CCK acts as an antagonist of the 
anxiolytic-like action of morphine. The interaction of 
BOC-CCK-4, a CCK, receptor agonist, and L-365, 260, a 
CCK, receptor antagonist, with morphine was studied in 
the elevated plus-maze model of anxiety. Simultaneously, 
the locomotor activity o f animals was measured in the 
motility boxes to exclude the unspecific interaction with 
the locomotor activity in rats.
M ATER IAL AND M ETH O D S
Animals
Male Wistar (Han/Kuo: WIST) rats (National Animal 
Centre, Kuopio, Finland) weighing 250-300 g were kept 
four per cage in the animal house at 20 ± 2C in 12 h 
light/dark cycle (light on at 07:00). Tap water and food 
pellets were available ad libitum. All subjects were 
experimentally naive and, apart from routine husbandry, 
were not specifically handled prior to testing.
The elevated plus-maze
The method initially suggested by Handley and 
Mithani1* for the measurement of exploratory activity 
was employed in rats with some modifications.17 The 
apparatus consisted of two opposite open arms (50 x 10 
cm) without side walls and two enclosed arms (50 x 10 x 
40 cm) with side walls and end wall, extending from a 
central square (10 x 10 cm). The maze was elevated to 
the height of 50 cm, and placed in a lit room. During a
5 min observation session the following measures were 
taken by an observer: 1) time spent in exploring of open 
part and open arms of plus-maze; 2) number of closed 
and open arm entries; 3) number of line crossings in 
open part; and 4) ratio between open and total arm 
entries. At the beginning of experiment an animal was 
placed into the center of plus-maze, facing toward an 
open arm. An arm entry was counted only when all four 
limbs of the rat were within a given arm. The animals
were brought into the experimental room one hour 
before the experiment Each animal was used only once.
Motility test
Immediately after the plus-maze exposure the rats were 
placed into the motility boxes. The locomotor activity 
was measured by means of photoelectric motility boxes 
(448 x 448 x 450 mm) connected to a computer (TSE 
Technical & Scientific Equipment GMBH, Germany). 
Time in exploration (s), distance of exploration (in 
metres), number and duration o f rearing were registered 
during а'б min observation period.
Drugs
Morphine sulphate (Boehringer-Ingelheim), BOC-CCK-4 
(N-tert-butoxy-carbonyl-CCK-4, Sigma Co) and naloxone 
hydrochloride (Sigma Co) were dissolved in physiological 
saline (0.9 % sodium chloride solution). L-365,260 
(Merck Sharp & Dohme) was suspended in saline with 
the help of few drops of Tween-80 (Sigma Co). L-365,260, 
BOC-CCK-4 and naloxone were administered intraperi- 
toneally, whereas morphine was given subcutaneously. 
L-365,260 was administered 30 min before the experi­
ment, naloxone and BOC-CCK-4 were injected 20 min 
and morphine 15 min prior to the study.
Statistics
Results are expressed as mean values ± S.E.M. The data 
of behavioural studies were analysed using one-way 
analysis of variance (ANOVA). Post hoc comparisons 
between individual groups were performed by means of 
Duncan multiple range test using the Statistica for 
Windows software.
R ESU LTS
The subcutaneous administration of morphine 
(1 mg/kg), a ц-opioid receptor agonist, induced a signifi­
cant increase of exploratory behaviour in the elevated 
plus-maze (Figure 1). Morphine increased the number of 
open arm entries (F377 =  5.18, P < 0.01), time spent in 
open arm (F377 =  5.53, P <  0.01) and number of closed 
arm entries (F377 =  5.60, P <  0.01). However, the increase 
in the ratio between open and closed arm entries was not 
statistically significant (F377 =  2.56, P = 0.06, Duncan 
multiple range test P =  0.056,). This is probably due to 
the fact that morphine increased not only the number of 
open part entries, but also the number of closed arm 
entries. Despite the increase of close arm entries the 
administration of morphine (1 mg/kg) did not change the 
locomotor activity of rats in the motility box (Fig. 2). The
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Fig. 1 The effect of morphine (0.5-2.5 mg/kg), BOC-CCK-4 (1-50 
ng/kg) and L-365,260 (1-1000 ng/kg) on the exploratory behaviour 
of rats in the plus-maze.* -  P<  0.05 (compared to vehicle-treated 
rats, Duncan multiple range test after the significant one-way 
ANOVA). Vehicle: saline in the case of morphine and BOC-CCK-4 
and few drops of Tween-80 in saline in the case of L-365,260.
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Fig. 2 The effect of morphine (0.5-2.5 mg/kg) on the locomotor 
activity of rats in the motility box.' -  P < 0.05 (compared to saline- 
treated rats).
lower(0.5 mg/kg) and higher (2.5 mg/kg) doses of mor­
phine did not modify the exploratory behaviour of rats in 
the elevated plus-maze (Fig. 1). Nevertheless, the higher 
dose of morphine (2.5 mg/kg) tended to reduce the loco­
motor activity in the motility test (Fig. 2; rearing time F}74 
= 1.80, p =  0.16; Duncan multiple range test, P =  0.037). 
The other tested drugs (naloxone, BOC-CCK-4 and 
L-365,260) and their combinations with morphine (0.5-1 
mg/kg) did not modify the locomotor activity of rats.
The pretreatment of rats with naloxone (0.5 mg/kg), an 
opioid receptor antagonist, did not change the 
exploratory behaviour of rats, but antagonized the anxi­
olytic-like action of morphine (Fig. 3). Naloxone antago­
nized morphine-induced increase of the number of open 
arm entries (F341 =  4.30, p <  0.01), time spent in open arm 
(F341 =  4.61, P  < 0.01) and the number of closed arm 
entries (F341 =  5.93, P <  0.01). However, the antagonism
of naloxone against the increase in the ratio between 
open and total arm entries was not statistically significant 
(FJ4| =  1.65, P  = 0.19, Duncan multiple range test 
P=  0.056). The intraperitoneal injection of BOC-CCK-4, a 
selective CCK, receptor agonist, induced a dose-depen­
dent reduction of exploratory behaviour of rats in the 
plus-maze paradigm. One pg/kg of BOC-CCK-4 did not 
modify the behaviour of rats if compared to control rats 
(Fig. 1). However, the higher doses of BOC-CCK-4 (10-50  
pg/kg) induced the statistically significant reduction in 
the behavioural measures believed to reflect anxiety in 
rodents -  the number of open arm entries (F36S1 =  4,52, 
P < 0.01) and ratio between open and total arm entries 
(F36S, = 3.54, P <  0.05) (Fig. 1). Ten ng/kg of BOC-CCK-4 
blocked the anxiolytic-like action of morphine (the num­
ber of open arm time: F457 =  2.72, P <  0.05; time spent in 
open arm: F457 = 2.65, P <  0.05; the ratio between open
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Fig. 3. The effect of naloxone (0.5 mg/kg) on the anxiolytic-like 
action of morphine (1 mg/kg) in the elevated plus-maze. SS (saline 
+ saline); SM (saline + morphine); NS (naloxone + saline); NM 
(naloxone + morphine).' -  P<  0.05 (compared to saline-treated 
rats);* -  P  < 0.05 (compared to morphine-treated rats).
Fig. 4 The action of BOC-CCK-4 (1-50 jig/kg) on the anxiolytic­
like action of morphine (1 mg/kg) in the elevated plus-maze. SS 
(saline + saline); SM (saline + morphine); B1M (BOC-CCK-4 1 
цд/кд + morphine); B10M (BOC-CCK-4 10 цд/кд + morphine); 
B50M (BOC-CCK-4 50 цдЛсд + morphine).’  -  P < 0.05 (compared 
to saline-treated rats);* -  P<  0.05 (compared to morphine-treated 
rats).
and total arm entries; F<57 =  1.36, P =  0.25, Duncan mul­
tiple range test: P = 0.076), whereas the other doses of 
BOC-CCK-4 (1 and 50pg/kg) were ineffective (Fig. 4). 
Only one dose (10 ng/kg) of L-0365,260, an antagonist of 
CCK, receptors, tended to increase the exploratory 
behaviour of rats (Fig. 1). Namely, this dose of L-365,260 
increased the ratio between open and total arm entries 
(F47S =  3.05, P <  0.05) and time spent in exploration of 
open arm (F47g =  2.62, P< 0.05). The combination of 
L-365,260 (100 ng/kg) with the sub-effective dose of mor­
phine (0.5 mg/kg) induced a significant anxiolytic-like 
action in the elevated plus-maze. This dose of CCK 
receptor antagonist in combination with morphine 
increased the ratio between open and total arm entries 
(F457 =  2.72, P < 0.05; Fig. 5). The other doses of
L-365,260 (10 and 1000 ng/kg) did not modify the action 
of morphine.
DISCUSSION
An acute treatment with morphine, an agonist of 
ц-opioid receptors, induced at a low dose (1 mg/kg) a 
significant anxiolytic-like action in the elevated plus- 
maze. Morphine increased not only the number of open 
arm entries, but also the number of closed arm entries. 
Nevertheless, morphine (1 mg/kg) did not modify the 
locomotor activity in the motility box showing that the 
action of ц-opioid receptor agonist was specific in the 
elevated plus-maze. The anxiolytic-like action of mor­
phine was completely reversed by the opioid antagonist
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Fig. 5 The interaction ol L-365,260 (1-1000 ng/kg) with the 
sub-effective dose of morphine (0.5 mg/kg) in the plus-таге.
VS (vehicle + saline); VM (vehicle + morphine); L10M (L-365,260 
10 ng/kg + morphine); L100M (L-365,260 100 pg/kg + morphine); 
L1000M (L-365,260 1000 pg/kg + morphine). Vehicle -  few drops 
of Tween-80 suspended in saline.' -  P<  0.05 (compared to 
vehicle-treated rats);*-  P<  0.05 (compared to morphine-treated 
rats).
naloxone. This is in a good accordance with a recent 
study of Motta and Brando.1 The higher dose of mor­
phine (2.5 mg/kg) did not cause the anxiolytic-like 
action. However, this dose of morphine seems to reduce 
the locomotor activity of rats. According to our previous 
studies 2.5 mg/kg) of morphine was able to block 
apomorphine-induced aggressiveness in rats.18 This 
behavioural effect of apomorphine is probably mediated 
via dopamine D2 receptors in the mesolimbic struc­
tures.19 The inhibition of the dopaminergic neurotrans­
mission in the mesolimbic structures seems to be a 
possible explanation why the higher doses of morphine 
are reducing the locomotor activity of rats.
The administration of BOC-CCK-4, an agonist of CCK, 
receptors, induced a dose-dependent reduction of 
exploratory behaviour in rats. According to our previous 
studies CCK agonists produced the anxiogenic-like 
action only in rats not acclimatized to the experimental 
situation.20 BOC-CCK-4 antagonized the anxiolytic-like 
effect of morphine, but CCK agonist possessed U-shaped 
action against morphine in the plus-maze. Namely, 
10pg/kg of BOC-CCK-4 reversed the anxiolytic-like 
effect of morphine, whereas the other doses of CCK ago­
nists were ineffective. The antagonistic interaction 
between the opioid agonist and CCK agonist is in 
accordance with our previous study where the opioid 
antagonist naloxone potentiated the anxiogenic-like 
action of CCK agonists (BOC-CCK-4 and caerulein).15 
Differently from BOC-CCK-4 only one dose (10 pg/kg) of 
L-365,260, an antagonist of CCK, receptors, modified 
the exploratory activity of rats. Namely, this dose of 
L-365,260 increased the exploratory behaviour of rats. 
The reversed U-shaped action of L-365,260 has been 
demonstrated also in our previous studies.21 The back­
ground of such action of L-365,260 is not clear and will 
need the further clarification. On the other hand, the 
combination of L-365,260 with the sub-effective dose of 
morphine (0.5 mg/kg) induced an anxiolytic-like action. 
However, again L-365,260 was effective only at one dose 
100 pg/kg. It is worthy to note that this dose of L-365,260 
did not change the exploratory activity of rats per see 
showing that the interaction between L-365,260 and 
morphine was specific. The potentiation of the action of 
morphine by the CCK, receptor antagonist could also be 
explained in the light of recent finding that morphine 
increased the release of CCK in the frontal cortex of rat.22 
Moreover, this dose of L-365,260 (100 pg/kg), but not the 
lower doses, antagonized the anxiogenic-like action of 
caerulein, an agonist of CCK receptors.20 Altogether 
these data re in favour of the antagonistic interaction 
between morphine and CCK in the regulation of 
exploratory behaviour.
There are several studies showing the negative interac­
tion between CCK and endopioid peptides in the regula­
tion of pain sensitivity. However, like in our studies the 
action of CCK was evident in rats not adapted to the 
experimental environment. Wiertelak et al.23 have shown 
that CCK antagonizes morphine-induced antinocicep­
tion only in the novel, but not in the familiar environ­
ment. This finding was confirmed by Lavigne et al.24 
demonstrating that CCK antagonists devazepide and 
L-365,260 enhance morphine-induced analgesia only in 
non-acclimatized rats exposed to the novel environment. 
Therefore, it is likely that even in the case of pain regula­
tion the interplay between CCK and endopioid peptides 
actually results on the level of anxiety. This suggestion is 
supported by the recent study of Benedetti et al.25
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Namely, they have found that nocebo induced hyperal­
gesia was reversed dose-dependently by CCK antagonist 
proglumide, but not by naloxone. Since the nocebo pro­
cedure represents an anxiogenic stimulus it is likely that 
nocebo hyperalgesia may be due to a CCK-dependent 
increase of anxiety.2S
According to the hypothesis of Wiertelak et al.23 the 
environmental stimuli that signal the occurrence of aver- 
sive or dangerous events activate endogenous opioid 
analgesia systems. The signals for safety (the nonoccur­
rence of aversive events) produce the opposite and 
inhibit environmentally produced analgesia. Wiertelak 
et al.23 believe that CCK is a mediator of that kind of 
safety signals. However, the present study as well as our 
previous study15 are not in favour of that statement since 
CCK apparently increases anxiety in the novel environ­
ment and reverses the anxiolytic-like action of morphine. 
Therefore, CCK is rather signalling that the novel 
environment is aversive and unsafe.
In conclusion, morphine potently increased the 
exploratory behaviour of rats in the elevated plus-maze. 
Namely, morphine increased the number of open arm 
entries and time spent in exploring of open part -  the 
behavioural measures believed to reflect the anxiolytic­
like activity in the plus-maze. The stimulation of CCK, 
receptors with BOC-CCK-4 apparently antagonized the 
anxiolytic-like action of morphine. The combination of 
the subeffective dose of morphine with L-365,260, a drug 
blocking the CCKj receptors, potentiated the effect of 
ц-opioid receptor agonist. Consequently, CCK is acting as 
the endogenous antagonist of anxiolytic-like action of 
morphine.
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ABSTRACT
In experiments on male W istar rats the influence o f pre-experim ental stress on the 
anxiogenic-like action o f caerulein, an agonist o f CCK receptors, was studied. Caerulein 
(5 fig/kg s.c.) caused the strongest action in animals brought to the experimental room 
immediately before the experiment and kept in isolation after the adm inistration of 
caerulein. Caerulein did not cause any reduction o f exploratory activity in rats made 
familiar to the experim ental room  and kept in the home-cage after the injection of the 
CCK agonist. The anti-exploratory action o f caerulein in stressed rats was reversed by 
the CCK antagonists L-365,260 (100 |ig/kg i.p.) and devazepide (100 |ig/kg i.p.), 
dem onstrating the involvement o f CCKB receptor subtype. In addition, seasonal 
fluctuations occur in the exploratory activity o f rats. The exploratory activity o f rats was 
much lower in July com pared to the study perform ed in November. The rats displaying 
the reduced exploratory activity had an increased number of CCK receptors in the 
frontal cortex and hippocampus. Simultaneously, the density o f serotonin 5-H T2 
receptors in the frontal cortex, but not that o f dopam ine D 2 receptors in the striatum, was 
elevated. The blood levels o f growth hormone were also higher in July. Accordingly, the 
anti-exploratory action o f caerulein is dependent on the pre-experimental stress o f rats. 
M oreover, the seasonal variations o f exploratory behavior o f rats are evident in the plus- 
maze model o f anxiety. The reduced exploratory activity in summer appeared to be 
related to the elevated density of CCK and 5-HT2 receptors in the brain. The results o f 
present study have been discussed in the light o f recent findings obtained from the 
human studies and some parallels between the animal and human data have been 
established.
Running title: CCK in a rat model o f anxiety
Key words: CCK; anxiety; elevated plus-maze; exploratory activity; seasonal varia­
tions; neurohormonal changes
1
INTRODUCTION
Cholecystokinin octapeptide (CCK-8) is a widely distributed neuropeptide in the 
mammalian brain (Rehfeld and Nielsen, 1995). Recent evidence suggests that CCK-8 is 
implicated in the neurobiology of anxiety (Harro and others, 1993). The anxiogenic-like 
action of CCK agonists is established in various animal species including the monkey, 
guinea-pig, rat, mouse and cat (Shlik and others, 1997a). CCKB receptor (brain subtype) 
antagonists are effective in antagonizing the anxiogenic-like action of CCK agonists, but 
they also cause an anxiolytic-like effect in various animal models of anxiety (Harro and 
others, 1993). There is a growing body of evidence that the administration of CCKB 
receptor agonists CCK-4 and pentagastrin induces panic-like attacks in healthy 
volunteers and patients suffering from panic disorder (De M ontigny, 1989; Bradwejn 
and others, 1991; Van M egen and others, 1994). The sensitivity o f panic patients to the 
panicogenic action o f CCKB agonists is significantly higher com pared to that o f healthy 
subjects (Bradwejn and others, 1994). The striking similarity between CCK-induced 
panic-like attacks and natural attacks has been established in panic patients. The 
augmented response to CCK agonists is also described in patients suffering from the 
other anxiety disorders (Shlik and others, 1997a). Accordingly, increased sensitivity to 
CCKB receptor agonist-induced panic-like attacks seems to be a common feature of 
anxiety disorders. The pretreatm ent o f healthy subjects with CCKB receptor antagonists 
blocks the panicogenic action o f CCK agonists, dem onstrating the implication o f CCKB 
receptors (Bradwejn and others, 1995).
There is some evidence that the response of rats to the anxiogenic-like action of 
CCK may be dependent on the level o f pre-experim ental stress (Harro and others, 1993). 
Biro and others (1993) have dem onstrated that the anxiogenic-like action o f CCK is 
related to the release o f corticotropin-releasing hormone (CRH). CRH is obviously 
playing a key role in the behavioural and hormonal mechanisms of stress (Chrousos and 
Gold, 1992). Recent studies have shown that mice lacking CRH1 receptor display 
impaired stress response and reduced anxiety in the light/dark com partment test (Timpl 
and others, 1998; Smith and others, 1998). The results obtained from the clinical studies 
provide some evidence for an involvement o f neuronal CRH in anxiety disorders, but 
not to the same extent observed in the case of depression (Jolkkonen and others, 1993; 
Fossey and others, 1996; Smith and others, 1989; Arborelius and others, 1999). Patients 
suffering from panic disorder display increased sensitivity to CRH-induced ACTH and 
cortisol release (Curtis and others, 1997). The administration of the CCKB receptor 
agonists CCK-4 and pentagastrin is shown to activate the hypothalam ic-pituitary-adrenal 
axis (De M ontigny 1989; Abelson and others, 1994; Koszycki and others, 1996). In their 
recent study Koszycki and others (1998) have described that the adm inistration of CCK- 
4 significantly enhanced ACTH secretion in healthy volunteers responding with panic­
like attacks com pared to non-responders. Therefore, in the present study an attem pt was 
made to clarify the significance of pre-experim ental stress in the anxiogenic-like action 
of CCK. For that purpose one half of the rats was habituated to the experimental 
situation, but the others were not.
Several investigators have described the seasonal fluctuations in anxiety. Recent 
reports have described a higher summer incidence in the occurrence of the first panic 
attack (Cameron, 1989; Lelliott and others, 1989; Lepine and others, 1991) irrespective
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of the hem isphere in which the study was carried out. Lelliott and others (1989) have 
found that o f 57 patients with panic disorder with agoraphobia more had their first panic 
in late spring and summer than in fall and winter, and in warm weather than in cold 
weather. Therefore, the second m ajor goal for the present study was the revealing of 
differences in anxiety o f rats in summer and winter, and the role o f CCK in these 
behavioral alterations. Simultaneously, changes in the density o f serotonin 5-HT2 and 
dopam ine D2 receptors, but also in the blood levels o f anterior pituitary hormones 
(prolactin, growth hormone and thyrotropin), were studied.
METHODS
Animals
M ale W istar (Han/Kuo: W IST) rats (National Animal Center, Kuopio, Finland) 
weighing 250-300  g were kept 4 per cage in the animal house at 20±2C in a 12h 
light/dark cycle (light on at 7.00 a.m.). Tap water and food pellets were available ad  
libitum.
The behavioural studies
Two different studies have been performed. In the first part (study was perform ed in 
Novem ber and December) an attem pt was made to reveal the significance o f pre- 
experimental stress on CCK-induced anxiety in the elevated plus-maze. The male W istar 
rats were divided into four different groups. Two groups of rats were handled in the 
experimental room  on three consecutive days (twice daily) before the experiment. The 
other two groups o f animals were brought to the experimental room  immediately before 
the beginning o f experiment. The handled and non-handled rats were divided into two 
groups after the injection o f caerulein (5 |ig/kg s.c., Sigma), an agonist o f CCK 
receptors. Caerulein or saline was injected 15 min before the beginning of the plus-maze 
study. One half o f animals was isolated after the injection, whereas the other half was 
placed back into the home-cage. The action o f the CCKB antagonist L-365,260 
(1 -100  |ig/kg i.p., M erck Sharp & Dohme) and CCKA antagonist devazepide 
(1 -100  |ig /kg i.p., M erck Sharp & Dohme) on the anxiogenic-like action of caerulein 
was also studied. CCK antagonists or vehicle (2% Tween-85 in physiological saline) 
were injected 30 min before the plus-maze study.
In the second half o f the experiment, possible seasonal differences in the exploratory 
activity of rats were studied. Two studies were perform ed - one study was conducted at 
the beginning o f July 1993 (summer) and the other one in late Novem ber o f 1994 
(winter). This study was perform ed in 40 handling-naive rats (in both experiments). The 
animals were decapitated immediately after the plus-maze exposure and the blood and 
brain samples were taken for neurohormonal studies.
The elevated plus-maze
The method initially suggested by Handley and M ithani (1984) for the measurem ent of 
exploratory activity was em ployed with some modifications (Pellow and others, 1985). 
The apparatus consisted of two opposite open arms (50x10 cm) without side walls and 
two enclosed arms (50x10x40 cm) with side walls and an end wall, extending from  a
central square (10x10 cm). The maze was elevated to the height o f 50 cm, and placed in 
a lit room. During a 5 min observation session the following measures were taken by an 
observer: 1) latency o f first open part entry; 2) time spent in exploring o f open part and 
open arms of plus-maze; 3) number o f closed and open arm entries; 4) number of lines 
crossed and 5) ratio between open and total arm entries. At the beginning o f experim ent 
an animal was placed into the centre o f plus-maze, facing toward a closed arm. An arm 
entry was counted only when all four limbs o f the rat were within a given arm. Time 
spent in open arms, number o f open arm entries and ratio between open and total arm 
entries are the “classical” measures o f anxiety in the elevated plus-maze (Rodgers and 
Johnson, 1995). By contrast, the number of closed arm entries and number o f line 
crossings are the measures reflecting the locomotor activity of rats (Rodgers and 
Johnson, 1995V
Hormonal studies
The animals were killed by decapitation immediately after the plus-maze exposure. In all 
cases the truncal blood was collected, serum was separated by centrifugation and 
samples were stored at -2 0 °C  until prolactin, thyrotropin and growth hormone 
concentrations were determined from duplicate samples (0.1 ml) by specific radio­
immunoassays. The rat prolactin, thyrotropin and growth hormone kits were gifts from 
NIH. Prolactin results are expressed in ng/ml of NIDKK-rPRL-RP-2 standard. Thyrotro­
pin data are expressed in ng/ml of N IDKK-TSH-RP-2 standard. Growth hormone results 
are expressed in ng/ml o f NIDKK-GH-RP-2 standard. Each hormone was assayed in a 
single session. The intra-assay coefficient o f variation was less than 15%.
Radioligand binding studies
For the radioligand binding studies 28 rats from the study performed in summer and 
28 animals from the experim ent conducted in winter were used. After decapitation the 
brains were quickly dissected on ice. The binding studies were performed in various 
brain structures o f rats. The striatum was used to determine the density and affinity of 
dopam ine D 2 receptors, the frontal cortex for 5-hydroxytryptamine 5-HT2 and 
CCK receptors, and the hippocampus for CCK receptors (Table 1). These brain 
structures were selected according to previous studies since in these brain regions the 
most significant neurochemical changes due to the elevated plus-maze exposure had 
been established (Rägo and others, 1988, 1991; Harro and others, 1990; Rex and others, 
1993; File and others, 1993). The brain tissue was homogenized in 20 volumes o f ice- 
cold 50 mM Tris-HCl (pH 7.4 at 4C) using a Potter-S glass-teflon homogenizer 
(1000 rpm, 12 passes). The membranes were washed twice in the same buffer by 
centrifugation (48000xg for 20 min) and resuspension. After the last centrifugation the 
crude brain m embranes were suspended in the incubation buffer for the appropriate 
binding assay.
The protein content was measured according to a dye-binding assay (Bradford, 
1976). Saturation curves were analyzed using non-linear least squares regression 
(Leatherbarrow, 1987).
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Statistics
Results are expressed as mean values ± S.E.M. The behavioural studies with caerulein 
and CCK antagonists were analysed using one-way analysis o f variance (ANOVA). Post 
hoc com parisons between individual groups were performed by means of the Newman- 
Keuls test using the Statistica for W indows software. The comparison of experiments 
performed in July and Novem ber was assessed by means o f the S tudent’s t-test.
RESULTS
The anti-exploratory action o f caerulein (5 pg/kg) was dependent on the pre- 
experimental handling and isolation. Caerulein did not cause any reduction of 
exploratory activity in animals subjected to the handling and kept in the home-cage after 
the injection of the CCK agonist (Table 2). Caerulein tended to reduce the activity of 
rats who were not handled but kept in the home-cage. However, this change was not 
statistically significant. In the third group where the rats were handled but kept separated 
after the treatment, caerulein apparently reduced the exploratory activity o f rats in the 
elevated plus-maze. Caerulein displayed the strongest action in rats not subjected to the 
handling and kept in isolation after the treatm ent with the CCK  agonist (Table 2).
The anti-exploratory effect o f caerulein in these stressed animals (no handling + 
isolation) was dose-dependently antagonized by L-365,260 (1—100 pg/kg), an antagonist 
o f CCKB receptors (Table 3, time spent in open part F466=2.90, p<0.05; number of line 
crossings F4i66=3.18, p<0.05; number of open arm entries F466=2.53, p<0.05; time spent 
in open part F466=2.57, p<0.05; number of total arm entries F466=2.94, p<0.05; ratio 
between open and total arm entries F466=2.63, p<0.05). One pg/kg o f L-365,260, if 
administered together with caerulein, tended to reduce the locomotor activity since this 
com bination decreased the number of line crossings and total arm entries. However, 
10 pg/kg o f L-365,260 tended to antagonize the anti-exploratory action o f caerulein, 
whereas 100 pg/kg o f the CCK antagonist com pletely reversed the effect o f the 
CCK agonist. Ten pg/kg of L-365,260 increased per se the exploratory activity of 
stressed (no handling + isolation) rats in the elevated plus-maze (time spent in exploring 
of open arms, F361=2.62, p<0.05; ratio between open and total arm entries F3i61=3.05, 
p<0.05), whereas the lower (I pg/kg) and higher doses (100 pg/kg) o f CCKB antagonist 
were ineffective in this respect (Table 4). Devazepide, an antagonist o f CCKA receptors, 
also antagonized the action of caerulein in the plus-maze (Table 5, time spent in open 
part F4i35=4.79, p<0.01; number o f line crossings F4j35=4.88, p<0.01; number of total 
arm entries F435=3.02, p<0.05). The highest dose of devazepide (100 pg/kg) 
counteracted the anti-exploratory effect o f the CCK agonist. The adm inistration of 
devazepide as a single treatment did not affect the exploratory activity of rats in the 
plus-maze (Table 6).
The exploratory activity o f rats in Novem ber was significantly higher com pared to 
the similar study conducted in July (Table 7). All the studied plus-maze parameters were 
significantly different if  the data from these two studies were subjected to the statistical 
analysis. In summ er the rats displaying the reduced exploratory activity in the plus-maze 
had the higher densities o f CCK receptors in the frontal cortex and hippocampus 
compared to the rats in study performed in winter (Table 8). The number of 5-HT2 
receptors in the frontal cortex, but not dopam ine D2 receptors in the striatum, was also
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increased in summer. The animals from the studies in the different seasons also differed 
in levels o f growth hormone, but not o f thyrotropin and prolactin, in the blood (Table 9). 
The decreased exploratory activity of rats in summer appeared to be related to the 
increased levels o f growth hormone in serum.
DISCUSSION
In the present study a clear dependence of the anti-exploratory effect of caerulein on 
pre-experim ental stress was revealed. In animals made familiar with the experimental 
situation and kept in the home-cage after the injection of caerulein, the CCK agonist did 
not increase anxiety in the elevated plus-maze. On the other hand, in rats brought into 
the experimental room  immediately before the study and kept in the isolation after the 
treatment with caerulein, the CCK agonist caused a significant anxiogenic-like action. 
This finding is in good accordance with previous studies showing the presence o f an 
anxiogenic-like action o f CCK only in a novel environm ent (Dauge and others, 1989). 
M oreover, CCK antagonized morphine-induced analgesia in rats in novel, but not in 
familiar, experim ental conditions (W iertelak and others, 1992). Accordingly, caerulein 
seems to potentiate neophobia in rats. However, the novelty is not the only factor 
determining the action o f caerulein in the plus-maze. The keeping of rats in social 
isolation after the injection o f CCK also contributes to the action o f caerulein. In our 
previous studies we have found that the social isolation of rats for 7 days induced 
anxiety in animals, but also increased the density of CCK, but not benzodiazepine, 
receptors in the frontal cortex (Vasar and others, 1993). Therefore, it is likely that the 
social isolation o f rats sensitizes the animals to the anxiogenic-like effect o f caerulein. It 
has been shown that the pre-experim ental stress also increases the effectiveness of 
anxiolytic drugs in the plus-maze showing that the endogenous tone is an important 
factor in studying of anxiety in rodents (Rodgers, 1997). It is important to point that 
patients suffering from anxiety disorders are also more sensitive to CCK-4- and 
pentagastrin-induced panic attacks than healthy volunteers (Bradwejn and others, 1994; 
Shlik and others, 1997b). The characteristic feature o f anxiety disorders is the increased 
serum level o f stress hormones (ACTH, cortisol) (Abelson and others, 1994; Arborelius 
and others, 1999). Collectively, the level o f pre-experim ental stress is a factor 
determining a potential response both in animals and in man to the anxiogenic-like 
action of CCK agonists.
The potentiation o f neophobia induced by caerulein was dose-dependently 
antagonized by the CCK antagonists L-365,260 and devazepide. The highest dose 
(100 (ig/kg) o f L-365,260 and devazepide completely reversed the action of caerulein. 
The nearly equal potency o f L-365,260 and devazepide against caerulein makes it 
unlikely that this effect o f CCK antagonists is mediated primarily via CCKA receptors. 
This statement is based on the knowledge that devazepide has very high affinity for 
CCKA receptors and much better penetration, com pared to L-365,260, into the brain 
(Hargreaves and Lin, 1992). Therefore, the CCKB receptor subtype is a likely target for 
the anxiogenic-like action of caerulein. This is in agreement with the previous studies 
showing a key role o f CCKB receptors in CCK-induced anxiety both in the human and 
animal studies (Harro and others, 1995). The single treatment with L-365,260, but not 
with devazepide, induced the anxiolytic-like action in rats. However, the action of
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L-365,260 was not dose-dependent since only one dose o f the CCKB receptor antagonist 
(10 |ig/kg) was effective, and the lower and higher doses did not change the exploratory 
behaviour of rats. The U-shape action of L-365,260 has been also established in our 
previous studies (Harro and Vasar, 1991), but the background of this peculiar action 
remains to be established.
The present study also provides a strong evidence o f seasonal variations in the 
exploratory activity of rats. The comparison of exploratory activity of rats in two 
experiments, conducted in July (summer) and in Novem ber (winter), revealed a clear 
difference, namely that the exploratory activity o f rats was much lower in summer 
compared to winter. Similar results showing a significant variation in the exploratory 
activity o f rats in two studies, in Novem ber and in June, were obtained by Harro and 
others (1997). M oreover, it is important to stress that the anxiogenic-like action of 
caerulein is much weaker in summer com pared to the studies performed in winter (our 
unpublished data). This was a reason why the influence o f pre-experim ental stress to the 
anxiogenic-like action of CCK agonist was studied in winter, but not in summer. Also, 
these data are interesting in the light o f recent reports describing significantly higher 
summer incidence in the occurrence of the first panic attack com pared to winter 
(Cameron, 1989; Lelliott and others, 1989; Lepine and others, 1991, M arriott and 
others, 1994). The hypothetical reason for such seasonality is the increased activity of 
people which leads to overcrowding o f public places (Lelliott and others, 1989). In rats 
the increased level o f anxiety in summer could be explained by the higher pressure from 
the surrounding nature since in summer the number o f potential predators is much higher 
than is winter when the life in nature is apparently ceasing down. This statement is 
supported by the recent findings showing the seasonal fluctuations in the serum levels o f 
ACTH in a sand rat with the maximum concentration during the late spring and summer 
(Am irat and Brudieux, 1993).
The reduced exploratory activity of rats in summer appears to be related to the 
increased number of CCK receptors in the frontal cortex and hippocampus. Harro and 
others (1997) have reached the same conclusions, i.e. that in June when the exploratory 
activity was lower the density o f CCK receptors was higher in the frontal cortex, 
hippocampus and striatum, but not in the hypothalamus. In the light o f these data, it is 
likely that the tone o f CCKergic transm ission is higher in summer com pared to winter. 
This could be a possible explanation why the anxiogenic-like action of caerulein is much 
weaker in summ er since CCK receptors seems to be occupied by the endogenous ligand. 
In addition, we have noted an increased density of serotonin 5-HT2 receptors in the 
frontal cortex o f rats having decreased exploratory activity. By contrast, the num ber of 
dopam ine D2 receptors in the striatum remained unchanged. Accordingly, increased 
anxiety in rats seems to be related to the increased density o f CCK and 5-H T2 receptors 
in the forebrain.
In summer rats also had significantly increased levels o f growth hormone, whereas 
the levels o f prolactin and thyrotropin remained unchanged. A recent study has shown 
that healthy subjects respond to CCK-4 challenge with an increased level o f growth 
hormone, which was higher in those who panicked after CCK-4 than in non-panickers 
(Koszycki and others, unpublished observations). In a previous study we have also 
investigated the release o f anterior pituitary hormones in relation to the exploratory 
behavior ol rats (Kõks and others, 1997). In that study, neither the exposure o f rats to 
the plus-maze nor distinctive exploratory activity correlated with the serum levels o f the
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anterior pituitary hormones prolactin or thyrotropin. Only the concentrations of growth 
hormone were significantly different in the rats selected according to the exploratory 
behavior, that is the “non-anxious” rats had markedly lower levels of growth hormone 
compared to the “anxious” and intermediate groups. Anterior pituitary hormones are 
regulated by a m ultitude of classic neurotransmitters like 5-HT and dopam ine but also 
by neuropeptides (Tuomisto and M ännistö, 1985). It has been shown that 5-HT 
stimulates the baseline release of growth hormone and may be involved in the stress- 
induced growth hormone elevation in man (Charney and others, 1987). CCK also 
participates in the regulation of growth hormone. The activation of CCKA receptors 
inhibits growth hormone secretion while the activation of CCKB receptors caused an 
opposite effect (M ännistö and others, 1994; Peuranen and others, 1994). Therefore, the 
augmented levels o f growth hormone in the “anxious” animals might be caused by the 
increased activity of 5-HT and CCK in the brain.
In conclusion, the anxiogenic-like action of caerulein was dependent on pre- 
experimental stress in animals. The CCK agonist caused the strongest action in rats not 
adapted to the experimental conditions. In addition, seasonal variations o f exploratory 
activity were revealed in the present study. The rats were more active in winter than in 
summer. The reduced exploratory activity o f rats was apparently related to the increased 
density of CCK and 5-HT2 receptors in the brain. Also, the levels o f growth hormone 
were markedly higher in animals displaying reduced exploratory activity. There is a 
striking similarity between the animal and human studies. The obvious relation to stress, 
increased sensitivity to CCK and existence o f seasonal variations are also apparent in the 
case of human anxiety.
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Table 1. Basic data about the receptor binding methodology used in the studies
Receptor Ligand Specific activity Brain area Nonspecific
binding
Reference
Dopamine Di
5-hydroxy- 
tryptamine 5-HT2
CCK
[3H]-spiperone
[3H]-spiperone
[3H]-
pCCK-8
105 Ci/mmole 
105 Ci/mmole 
75 Ci/mmole
Striatum
Frontal cortex
Frontal cortex 
and hippocampus
Raclopride 
1 цМ
Ketanserin 
1 pM
Caerulein 100 
nM
Lang et al., 1992 
Langer a l ,  1992 
Lang et al., 1995
Table 2. The effect of handling and isolation on the anti-exploratory action of caerulein in the 
plus-maze
Han­
dling +
No isola­
tion +
Han­
dling +
Isola­
tion +
No han­
dling +
No isola­
tion +
No han­
dling +
Isola­
tion +
Parameters Saline Caerulein Saline Caerulein Saline Caerulein Saline Caerulein
Number of line 
crosssings
19±4 15±3 39±5 ■ 24+3* • 26+4 19±4 25±2.8 18±1.6
Number of open 
arm entries
1.6±0.6 1.1 ±0.4 3.6+0.7 1.7±0.5* 2.7+0.8 1.8±0.6 2.0±0.4 0.7±0.2*
Time spent in 
open arm (sec)
24+9 21±9 57±14 36+14 54±14 33±9 46± 11 14±6*
Number of total 
arm entries
5.8±1.2 4.7+0.7 11.4+1.0 7.7±0.9* 8.1 + 1.1 6.4±1.4 7.1±0.7 5.5+0.5
Ratio between 
open/total arm 
entries
19±5 21 ±7 36+5 22±6 28±8 19±5 27 ±4 9±3*
* —  p<0.05 (compared to the respective saline treated group, Newman-Keuls test after significant 
one-way ANOVA). Number of line crossings F7i92=4.58, p<0.01; number of open arm entries 
F7y2=3.36, p<0.01; time spent in open arm F792=2.31, p<0.05; number of total arm entries 
F7,92=4-51, pcO.Ol; ratio between open and total arm entries F7i92=2.79, p<0.05). Number of 
animals is 12 in each group.
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Table 3. The effect of L365,260 on the anxiogenic-like action of caerulein in the elevated plus-
maze
Vehicle+ Vehicle+ L365,260 
1 ng/kg+
L365,260 
10 ng/kg+
L365.260 
100 ng/kg+
Parameters saline caerulein 
5 |ig/kg
caerulein 
5 Mg/kg
caerulein 
5 ng/kg
caerulein 
5 |ag/kg
Number of line 
crossings
22±1.9 17+1.5 14±2.3* 18+1.8 22±2.0
Time spent in open 
part (sec)
135± 13 96±8 100±16 132±14 143±11**
Number of open arm 
entries
1.3±0.4 0.4±0.2* 0.4±0.2* 1,0±0.4 1.3+0.4**
Time spent in open
arm (sec)
30±10 5±3* 8±4 21 ±7 31±11**
Number of total arm 
entries
6.3±0.7 5.5±0.6 4.0±0.7* 5.4+0.6 6.9±0.6
Ratio between open/ 
total arm entries xlOO
19±5 6+2* 8±4 13+5 15±5
* — p<0.05 (compared to vehicle+saline treated rats; Newman-Keuls test after significant one­
way ANOVA); ** — p<0.05 (compared to vehicle+caerulein treated rats). Number of animals is 
14 in each group.
Table 4. The action of L-365,260 on the exploratory activity of rats in the plus-maze
Parameters Vehicle L-365,260 
1 M g / k g
L-365,260
10 M g / k g
L-365,260 
100 M g / k g
Number of line crossings 20+2.9 20±3.0 22±3.2 18±2.2
Time spent in open part (sec) 102±10 116±11 125±12 97±10
Number of open arm entries 0.9±0.27 1.1±0.33 1.6±0.40 0.7+0.24
Time spent in open arm (sec) 12±4 26±7 30±11* 8±3
Number of total arm entries 6.6+0.8 6.2+1.0 6.5+0.8 5.8±0.8
Ratio between open 
/total arm entries x 100
10±3 16±4 25+7* 8±3
* — p<0.05 (compared to vehicle treated group, Newman-Keuls test after significant one-way
ANOVA). Number of animals is 16 in each group.
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Table 5. The effect of devazepide on the anxiogenic-like action of caerulein in the elevated plus-
maze
Vehicle+ Vehicle+ devazepide 1
Mg/kg+
devazepide 10
Mg/kg+
devazepide 100
Mg/kg+
Parameters saline caerulein 
5 Mg/kg
caerulein 
5 Mg/kg
caerulein 
5 Mg/kg
caerulein 
5 Mg/kg
Number of line
crossings
19±2.2 8±1.6* 11+1.8* 11+3.3 19±2.5**
Time spent in open 
part (sec)
175±11 102±17* 126+19 82±23* 158±13**
Number of open arm 
entries
1.0±0.4 0.3+0.2 0.4±0.4 0.5+0.3 0.8±0.4
Time spent in open 
arm (sec)
21 ±12 8±6 10±7 9+5 21±12
Number of total arm 
entries
5.4±0.7 2.5±0.5 3.0±0.7 3.4±0.9 5.5±0.5
Ratio between open/ 
total arm entries x 100
16±6 7±5 5 ±5 11±6 11 ±4
* — p<0.05 (compared to vehicle+saline treated rats, Newman-Keuls test after the significant 
one-way ANOVA); ** — p<0.05 (compared to vehicle+caerulein treated rats). Number of 
animals is 8 in each group.
Table 6. The action of devazepide on the exploratory activity of rats in the plus-maze
Parameters Vehicle devazepide 
1 M g / k g
devazepide
10 M g / k g
devazepide 
100 M g / k g
Number of line crossings 14±3 .6 8±2.1 13±2.1 11±2.2
Time spent in open part (sec) 126±25 117 ± 19 10 9 ± 16 115±15
Number of open arm entries 0.8±0.31 0.6±0.32 0.3±0.16 0.3+0.16
Time spent in open arm (sec) 12±7 7±4 5±3 9±7
Number of total arm entries 4.6±1.1 2.9+0.7 3.8±0.8 4.0±0.9
Ratio between open/total arm 
entries x 100
10±4 13±7 6+4 4±3
Nunber of rats is 10 in each group.
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Table 7. The comparison of the results of two distinct experiments, performed in July and in 
November: plus-maze exploration
Plus-maze parameters July November
Number of line crossings 10±1 8±2*
Time in open part (sec) 46+6 91 ±6*
Number of open arm enrtries 0.2±0.1 1.3±0.3*
Time in open arm (sec) 4±2 14±3*
Number of total arm entries 3.1±0.3 7.8±0.6*
Ratio between open and total arm entries (xlOO) 4±2 19+4*
* — p<0.05 (Student’s r-test).
Table 8. The comparison of the results of two experiments, performed in July and in November: 
CCK, dopamine and 5-HT receptors in the brain
Radioligand binding in the 
brain structures
July November
[3H]pCCK-8 in the frontal K i(nM ) 0.87±0.08 0.79+0.05
cortex Bmax (fmol/mg protein) 8.7±0.4 6.1±0.3*
[3H]pCCK-8 in the Ku(nM) 0.77±0.07 0.58±0.06*
hippocampus Bmax (fmol/mg protein) 5.3±0.3 3.7±0.3*
[3H]spiperone in the striatum Kd(nM) 0.59±0.06 0.75±0.10
Bmax (fmol/mg protein) 214±8 198±8
[3H]spiperone in the frontal Kd(nM) 1.52±0.25 1.11+0.11
cortex Bmax (fmol/mg protein) 140± 18 106±5*
* — p<0.05 (Student’s f-test).
Table 9. The comparison of the results from two experiments, performed in July and in 
November: blood levels of hormones
TSH, ng/ml Growth hormone, ng/ml Prolactin, ng/ml
July 1.6±0.2 35±4 15±2
November 1.2±0.2 13+2* 11±1
* — p<0.05 (Student’s /-test).
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